{"title": "Author Index: P", "author": "P N; N", "url": null, "hostname": null, "description": null, "sitename": null, "date": "2015-01-01", "cleaned_text": "P N, N. Paardekooper, J. Paba-Prada, C. E. 375 - 3029 - 4217 - 4256 [Alliance and Pomalidomide Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival](Paper85666.html) 4217 - [A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma](Paper80503.html) 4256 - [Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with or Relapsed/Refractory Multiple Myeloma](Paper84071.html) Pabinger, 652 Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant Thrombosis Study (LATS)](Paper85460.html) 653 - [Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study](Paper85615.html) 718 - [Ristocetin-Induced Platelet Aggregation for Monitoring Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia](Paper80115.html) 1087 - [Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE](Paper79266.html) 3524 - [Rviii-Singlechain Pharmacokinetics and Safety in Children Less Than 12 Years of Age](Paper83381.html) 3525 - [Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Continuous and Bolus Infusion](Paper83701.html) 3555 - [Annexin A5 Resistance Is Associated with Thrombotic Risk in Patients with the Lupus Anticoagulant: The Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia](Paper84123.html) 3855 - [Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia](Paper83750.html) Pace, B. 282 - 410 - 962 - 969 - 3387 - [Pharmacological Induction of FOXO3 Is a Potential Treatment for Sickle Cell Disease](Paper82825.html) 410 - [Dimethyl Fumarate Induces Fetal Hemoglobin in Sickle Cell Disease](Paper85915.html) 962 - [Induction of Fetal Hemoglobin and Reduction of Disease Pathology in Sickle Cell Mice By a Synthetic Zinc Finger Gamma-Globin Activator](Paper85722.html) 969 - [Therapeutic Potential of Beta-Nicotinamide Adenine Dinucleotide to Reverse Endothelial Barrier in Mouse Model](Paper83143.html) 3387 - [Delta-Aminolevulinate Preferentially Induces Gamma-Globin Expression in Erythroid through Activation of NRF2 Stress Response](Paper85604.html) Pace, S. Pacharne, S. Pachlinger, R. L. Paci, A. Paciaroni, K. Paciello, G. Pacilli, A. 351 - 353 - 1627 - 1630 - 4087 - 4091 - [Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients](Paper80206.html) 353 - [Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors](Paper81593.html) 1627 - [A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study](Paper81061.html) 4091 - [Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes](Paper81892.html) Pacillo, S. Packham, - 1716 - 2917 4130 - [Genomic Disruption Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling](Paper84721.html) 2917 - [IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA Methylation of the IL-10 Locus](Paper84848.html) 4130 - [Biological Significance of B Cell Receptor Mediated Regulation of Autophagy in Chronic Lymphocytic Leukemia](Paper84928.html) Paczesny, S. Padayachee, S. Paddock, C. Paddock, M. N. Padella, A. 1356 - 2513 - 2600 - 2623 - 3837 - 3840 - 4085 - [A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of - [Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia](Paper86470.html) 2600 - [Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia](Paper85175.html) 2623 - [Clustering Adult ACUTE Lymphoblastic Leukemia By Whole Exome Sequencing (WES) Analysis](Paper85431.html) 3198 - [Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients](Paper84760.html) 3627 - [RNA Sequencing Reveals Novel and in Acute Myeloid Leukemia](Paper84605.html) 3837 - [Novel Leukemia](Paper83864.html) 3840 - [A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium](Paper83956.html) 4085 - [Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number [Leukapheresis Reduces 4-Week Mortality in Leukemia Patient with Hyperleukocytosis-a Retrospective Study from a Tertiary Center](Paper86829.html) 4118 - [Systematic Drug Repositioning By Integrating Transcriptome and Historical Clinical Data, Identification of Digoxin As a Novel Drug Reposition Candidate for High-Risk Myelodysplastic Syndromes](Paper86669.html) Padmanabhan, P. Padmanabhan, R. Padrnos, L. Padron, 286 - 907 - 1641 - 1664 - 1673 - 4382 - [Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype](Paper85355.html) 286 - [Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition](Paper86225.html) 907 - [Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee](Paper83382.html) 1641 - [Molecular Characterization of SRSF2 Mutation Identifies Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML)](Paper83350.html) 1664 - [Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS)](Paper81534.html) 1673 (MDS): A Chromosome 3 Abnormalities](Paper86434.html) 2112 - [What Is the Impact on Quality of Life of Various Treatments in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome? Rethinking the Goals](Paper82145.html) 2888 - [A Novel Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Cautionary [Refining Triage to Polycythaemia Vera or Primary Myelofibrosis Based on Targeted Molecular Profiling By Clinical Next Generation Sequencing](Paper83007.html) 4121 - [P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Burden Adverse in Myelodysplastic Syndromes](Paper85180.html) 4382 - [TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Derangement in Follicular Lymphoma Patients Severe Effects during Treatment with PI3K Inhibitors](Paper80516.html) 3933 - [Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL)](Paper80250.html) Paganin, Hematological Patients Colonized By Prospective Observational Seifem Study](Paper80831.html) 3566 - [Granulocyte Transfusions at Appropriate Doses Improve in Hematological Patients with Febrile Neutropenia](Paper86351.html) 3757 Klebsiella Onco-Hematological Patients: Incidence and Clinical Impact of Resistance in a Multicentre Prospective Survey](Paper83609.html) 4085 - [Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis](Paper85684.html) Page, D. B. Page, J. H. Page, K. M. Page, L. Pagel, J. M. 254 - 2728 - 3794 - [A Phase 1 Study of a Phase Rituximab for Patients with B-Cell 3794 and (AML)](Paper81957.html) Pageon, L. Paggetti, J. Paglia, M. Pagliara, D. 195 - 1931 - 3107 - [Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome](Paper84874.html) 1931 - [Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): of a Phase I-II Trial](Paper85451.html) 3107 - [Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation or Chemotherapy--Results from the Italian Therapeutic Use Protocol](Paper80304.html) Pagliarini, D. J. Pagliuca, A. 347 - 2331 - 2334 - 2335 - 3129 - [Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML](Paper84478.html) 2331 - [Patients Prescribed Warfarin with Poor Time in Therapeutic Range (TTR) Have Different Beliefs about Their Illness and Anticoagulation Therapy Compared to Those with a Good TTR - Early Results from the Switching Study](Paper80129.html) 2334 - [Rivaroxaban-Mediated Vascular Relaxation As a Potential Cause of Headaches and Dizziness](Paper80791.html) 2335 - [Do the Safety and Efficacy Outcomes Reported in the Clinical Trials of Direct Oral Anticoagulants (DOAC) Translate to the Real-World?](Paper81914.html) 3129 - [Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease](Paper82890.html) Pagliuca, S. 153 - [Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)](Paper82068.html) Pagnani, A. Pagnano, K. B. Pagotto, S. Pahl, H. L. Pahl, H. L. Pai, M. Pai, S. Y. Paietta, E. 217 - 693 - 787 - 795 - 796 - 1308 - 1315 - 1422 - 2591 - 2618 - 2702 - [North American Leukemia Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age 60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)](Paper80738.html) 693 - [Expression of an Oncogenic ERG B-Progenitor Acute Leukemia](Paper83996.html) 787 - Myeloid - [in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993](Paper84387.html) 796 - [Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60](Paper78435.html) 1308 - [Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902](Paper81390.html) 1315 - [Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience](Paper80407.html) 1422 - ALL](Paper86546.html) 2591 - [A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML](Paper83376.html) 2618 - [High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults](Paper83106.html) 2702 - [Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the 2 Paietta, C. Myeloma](Paper82549.html) 2923 - [Prognostic Implications of PIM-2 Expression in Samples from Patients with Chronic Lymphocytic Leukemia and Impact in the Sensitivity to the Pan-PIM Kinase Inhibitor PIM447](Paper82102.html) Painter, D. Painter, J. Paiva, B. 19 - 117 - 367 - 721 - 725 - 1848 - 2955 - 2963 - 2972 - 4180 - 4181 - 4243 - SCI-52 - [Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials](Paper81690.html) 117 - [Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma](Paper80733.html) 367 - [Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)](Paper80461.html) 721 - [Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study](Paper81654.html) 725 - [What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity](Paper81675.html) 1848 - [Bortezomib, Melphalan, (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years](Paper83068.html) 2955 - [Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma 2972 - [Simplified in-House Method of Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma](Paper80145.html) 4180 - [Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)](Paper80476.html) 4181 - [The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients](Paper81680.html) 4243 Followed Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)](Paper81735.html) - - 1614 - 2799 - 4094 - [Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients](Paper84407.html) 1614 - [JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome](Paper84338.html) 2799 - [Safety and Efficacy of of JUMP: An Patients Factors of the Inflammatory Microenvironment (IL-1 Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in CD34+ Cells](Paper82772.html) C. S. 3279 - 4050 - [Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States](Paper86308.html) 4050 - [Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal](Paper83405.html) Palis, J. 405 - 1170 - 2372 - 3597 - [Fam210b Is Required for Cellular Mitochondrial Iron Uptake during Erythroid Differentiation](Paper80615.html) 1170 - [Temporally Distinct Waves Stem Cells](Paper84913.html) 2372 - [Definitive Erythro-Myeloid Progenitors (EMPs) Emerge in the Myb-/- Embryo and Retain the Capacity to Differentiate into Macrophages](Paper85034.html) 3597 - [Prostaglandin E2 Promotes the Sequential Recovery of Bone Marrow Vasculature and the Megakaryocyte Lineage Following Radiation Injury](Paper82175.html) Palisch, C. W. Palla, S. Palladas, P. Palladini, 1773 - 3049 - 3292 - [Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients](Paper85067.html) 1773 - [Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome](Paper85505.html) 3049 - [The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis](Paper84053.html) of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)](Paper86120.html) Palladino, C. Pallavi, R. Pallavi, N. 824 - 4057 - [Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study](Paper85751.html) 4057 - [A Heterogeneous Response Pattern to Interferon-alpha2 with Induction of a Significant Decrease in the Calreticulin Mutant Allele Burden in a Subset of Patients with Essential Thrombocythemia and Primary Myelofibrosis](Paper82441.html) Palma, J. Palma, M. Palma, M. Palmaro, A. Palme, I. Palmer, A. Palmer, J. 1347 - 2818 - 3808 - 4370 Neoplasms: A Single Center Experience](Paper85382.html) 3808 - [A Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results](Paper81837.html) 4370 - [The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly](Paper79326.html) Palmer, J. 519 - 522 - 735 - 1961 - 3179 - [Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT](Paper79185.html) 522 - [Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation](Paper83188.html) 735 - [A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia](Paper86435.html) 1961 - [Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation](Paper78900.html) 3179 - [Radioimmunotherapy-Based Conditioning with Tiuxetan Plus Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?](Paper83402.html) Palmer, J. M. Palmer, K. A. 643 - 2473 - 2549 - 3659 - 4218 - [MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells](Paper81186.html) 2473 - Acute Myeloid Leukemia](Paper79441.html) 2549 - [DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions](Paper80788.html) 3659 - [Immunomodulatory Effect of of PD-1 Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease](Paper80695.html) Palmi, C. Palmieri, G. 3653 - 3841 - [Up-Regulation of in Acute Myeloid Leukemia](Paper78532.html) 2446 - [The Role of MLL-AML](Paper81240.html) 3653 - [A Tumor Suppressor microRNA Defines in Acute Myeloid Leukemia](Paper80859.html) 3841 - [Patient-Tailored Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Next Generation Sequencing](Paper84354.html) Palodetto, B. Palomba, L. 470 - 1485 - Patients a Multicenter, Phase 2 Study](Paper78771.html) 1485 - [High-Depth, Targeted, Next Generation Identifies in T-Cell Lymphoma](Paper85911.html) Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability](Paper86981.html) 1540 - [Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia](Paper84534.html) 2668 - [Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive [Veliparib (ABT-888), Bendamustine, and Rituximab Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma](Paper84188.html) Palomba, P. Palomera, - 2962 - 4180 - [Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients](Paper80683.html) 725 - [What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity](Paper81675.html) 1514 - [Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): of GEM/Pethema Clinical Trials](Paper80997.html) 4180 - [Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)](Paper80476.html) Palomero, T. Palomo Bravo, A. Palomo, 2883 - 2905 with a Post-Translational Reduction of BRCA1 Levels and Independent of Promoter Methylation](Paper83716.html) 2883 - [Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features](Paper78728.html) 2905 - [Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol from CETLAM Group)](Paper79704.html) Palomo, T. Paltiel, O. B. Paltuev, R. Paluch, B. E. Palumbo, A. 28 - 30 - 392 - 507 - 510 - 727 - 729 - 731 - 927 - 1760 - 1814 - 1828 - 1834 - 1844 - 1974 - 2093 - 3029 - 3031 - Phase Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up](Paper79218.html) 30 - [Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)](Paper82083.html) 392 - [Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial](Paper78741.html) 507 - [Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)](Paper79032.html) 510 - [Elotuzumab Plus Bortezomib and Dexamethasone Versus Multiple 727 - [Ixazomib, an Investigational Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)](Paper79829.html) 729 - [Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)](Paper81814.html) 731 - [Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)](Paper80240.html) 927 - [Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79550.html) 1760 - [Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study](Paper79067.html) 1814 - [Proteomic Characterization Newly Diagnosed Myeloma Patients: Results of a Phase 2 Study](Paper79554.html) 1834 - [Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone 1844 - [Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup](Paper82133.html) 1974 - [Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79710.html) 2093 - [An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival](Paper79223.html) 3029 - [Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Survival](Paper85666.html) 3031 - [Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment](Paper79875.html) 3034 - [Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice](Paper79826.html) 4225 - [An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM (RRMM)](Paper80851.html) 4239 - [A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial](Paper81170.html) 4250 - [Serial Echocardiographic Assessment of Patients (Pts) Myeloma Carfilzomib 3 Trial (NCT01568866)](Paper81422.html) Palumbo, G. 2501 - 3093 - [Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics](Paper82546.html) 3093 - [Immune Reconstitution after Adoptive Infusion of BPX501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary and Functional Results of a Phase I-II Trial](Paper85151.html) Palumbo, G. A. Palumbo, G. A. 91 - 1614 - 2799 - 4018 - [Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial](Paper85411.html) 1614 - [JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome](Paper84338.html) 2799 - [Safety and Efficacy of of JUMP: An Patients with Myelofibrosis](Paper80642.html) 4018 - [Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients](Paper81880.html) C. Pamer, E. Pampillo, M. Pamukcu, R. Pan, C. Pan, C. Pan, D. Pan, J. Pan, J. Pan, K. T. Pan, L. Pan, L. Pan, L. Pan, R. 328 - 673 - 1198 - [Mechanisms of Acquired Resistance - RG7388 Reciprocally Overcome Leukemia Apoptosis Resistance to Either Efficacy and Mechanisms](Paper85569.html) 1198 - [Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment](Paper85483.html) Pan, S. Pan, Y. Pan, Y. 1876 - 1885 - [Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Transplantation](Paper78902.html) - [TNF-Alpha Enhances CD4+FoxP3+ Suppressive Function in GvHD Prevention and Treatment](Paper83636.html) Pan, Z. Pan, Z. Pan, Z. Panagiota, V. Panagiotidis, I. 1832 - 3045 - 4251 - [Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis](Paper80479.html) 3045 - [Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma](Paper81864.html) 4251 - [Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease](Paper81591.html) Panagiotidis, P. Panagiotidis, Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations](Paper80448.html) 1712 - [ATM Mutations in Major Stereotyped is 2865 - [Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes A. Panch, S. Panchabhai, S. Pancrazzi, A. 351 - 353 - 1627 - 1630 - 4087 - 4091 - [Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients](Paper80206.html) 353 - [Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors](Paper81593.html) 1627 - [A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study](Paper81061.html) 4091 - [Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Driver [Predicting Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates](Paper83736.html) 3929 - [Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients Malignancies](Paper79625.html) Pandey, R. Pandey, S. Pandita, T. Pandya, R. Pane, 346 - 1570 - 1693 - 2792 - 4046 - [BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and and Second-Line Tyrosine Kinase Conventional Sequencing?](Paper83694.html) 1570 - [Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib](Paper84611.html) 1693 - First-Line WP Analysis](Paper82401.html) 4046 - Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial](Paper82672.html) Paneesha, S. Panepinto, J. A. 281 - 525 - 526 - 2190 - 3291 - 4489 - - - [Sickle Cell Disease Measures in the Phenx Toolkit](Paper85699.html) 525 - [Higher Dose of Opioids in the Emergency Department and Earlier Initiation of Oral Opioids after Hospitalization Are Associated with Shorter Length of Stay in Children with Sickle Cell Disease Treated for Acute Pain](Paper87135.html) 526 - [Clinically Meaningful Interpretation of Quantitative Sensory Testing As a Measure of Pain Sensitivity in Patients with Sickle Cell Disease](Paper87147.html) 2190 - [The Neuropeptide Substance P Is Elevated in Patients with Sickle Cell Disease](Paper80782.html) 3291 - [Patient-Reported Outcome Measures Identify Impairment Better Than Clinician Documentation during Pediatric Cancer Treatment](Paper83970.html) 4489 - [Pediatric Leukemia/Lymphoma Patients Have Worse Patient-Reported Health Status Than Pediatric Solid Tumor and CNS Tumor Patients during Intensive Treatment](Paper84006.html) - [Patient-Reported Outcomes in Clinical Practice](Paper77379.html) - [Plenary Introducer](Paper87234.html) Panepucci, R. A. Panetta, J. C. 1299 - 3120 - 4322 - [Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia](Paper81709.html) 3120 - [Population Pharmacokinetics of Fludarabine and Transplantation](Paper82357.html) - [Generic Intravenous Busulfan Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring](Paper84243.html) Panetta, J. C. Pang, Q. Pang, X. Pangalis, G. Pangalis, G. A. Panganiban, J. Pangault, C. Panholzer, Paniagua, C. C. 1494 - 2704 [CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma](Paper84929.html) 2704 - [CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma](Paper85948.html) Panjwani, R. Pannecouque, C. Panoskaltsis, N. Panoskaltsis-Mortari, A. 147 232 - 1878 - 3079 - SCI-8 - [Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality](Paper81383.html) 232 - [Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion](Paper83158.html) 1878 - [Th17/Th22 Cells Mediate Breakthrough Graft-Versus-Host-Disease](Paper85282.html) 3079 - Stem Cell Memory Dynamics during Acute Graft-Versus-Host Disease](Paper85629.html) SCI-8 - [Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease](Paper77238.html) Panozzo, S. Panse, J. P. Pantani, L. - 2961 - [An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival](Paper79819.html) 927 - [Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79550.html) 2961 - [The Alternate Activation of Hedgehog Pathway, Either in CD138+ or in CD138-CD19+ Multiple Myeloma Primary Cells, Impacts on Disease Outcome](Paper80482.html) Pantani, Pantel, Panteliadou, - 2538 - 4260 - [Influence of Different Components of the Tumor Microenvironment Human Lymphoma Cell Engraftment Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis](Paper85551.html) 2538 - [Establishment and Characterization of a Panel of Patient-Derived Acute Leukemia Mouse Models As Emerging Platform for Translational Research](Paper82821.html) 4260 - [Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTM\u00c2 - - 2803 - 4087 - [Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors](Paper81593.html) 1615 - [IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers](Paper81040.html) 2803 - [Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative 4087 - of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study](Paper81061.html) Paolini, S. Paolini, S. Paoloni, F. Papa, E. Papa, E. Papadaki, H. A. Papadaki, T. Papadimitriou, S. Papadopoulos, E. B. 1911 - 2123 3095 3231 - 4320 - 4332 - [Impact of Busulphan Exposure on Transplant Outcomes for Patients with Advanced Myelodysplastic Syndromes Undergoing at Memorial Cancer Center](Paper83431.html) 3095 - [Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies](Paper85469.html) 3231 - [Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies](Paper85412.html) 4320 - [Infection Burden of Double Stranded Viruses after CD34+ Selected, T-Cell Depleted (TCD) Hematopoietic (HCT) Dose Unfractionated Heparin (UFH) Prophylaxis Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients](Paper86482.html) Papadopoulos, K. P. Papadopoulos, P. Papadopoulou, A. 622 - 1926 - [Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the and 1926 - [Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years](Paper79439.html) Papadopoulou, A. Papadopoulou, E. Papaemmanuil, E. 85 - 140 - 803 - [Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data](Paper84855.html) 140 - [Sf3b1 K700E Mutation Impairs Pre-mRNA Splicing and Definitive Hematopoiesis in a Conditional Knock-in Mouse Model](Paper85888.html) 803 - [Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML](Paper82044.html) Papaemmanuil, E. 166 - 710 - 907 - 1426 - [Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia](Paper86992.html) 710 - [An Integrative Genomics Approach Uncovers the Resistance to AZA Therapy in MDS and CMML](Paper82473.html) 907 - [Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee](Paper83382.html) 1426 - [Clincial and Genetic Landscapes Differ P2RY8-CRLF2 Leukaemia](Paper78936.html) Papageorgiou, A. - 2921 - [Survival Advantage with Comparable Complete Chimerism Patterns in Reduced Toxicity Treosulfan-Based Vs Reduced Intensity Busulfan-Based Conditinioning Regimen in Allogeneic Haematopoietic Cell 2921 - [Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?](Paper80972.html) Papalexi, E. Papalinetti, G. Papanagnou, E. D. Papanicolaou, Transplantation (HCT): Clinical Experience at Memorial Sloan-Kettering Cancer Center](Paper83431.html) 3303 - [Burden of Pneumococcal Disease in Cancer Patients: A 20 Year Single Center Study at Memorial Sloan-Kettering Cancer Center](Paper79853.html) 4320 - [Infection Burden of Double Stranded (dsDNA) Viruses after CD34+ Selected, T-Cell Depleted (TCD) Hematopoietic (HCT) Cancer Center Papanikalaou, Papanikolaou, N. Papanikolaou, X. - 1806 - 3181 - [47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma](Paper86501.html) 1806 - [The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma](Paper85442.html) 3181 - [A Benefit Added Bortezomib, Thalidomide with DNA Damage Response Pathway](Paper83110.html) 1356 - [A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of - [The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia](Paper84493.html) 2489 - [Clinical Relevance of Low Burden BCR-ABL1 Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type Mutation Matters](Paper83318.html) 2513 - [Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia](Paper86470.html) 2600 - [Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia](Paper85175.html) 2623 - [Clustering Adult ACUTE Lymphoblastic Leukemia By Whole Exome Sequencing (WES) Analysis](Paper85431.html) 3198 - [Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients](Paper84760.html) 3627 - [RNA Sequencing Reveals Novel and in Acute Myeloid Leukemia](Paper84605.html) 3837 - [Novel Leukemia](Paper83864.html) 3840 - [A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium](Paper83956.html) 4085 - [Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis](Paper85684.html) Paquette, Paradiso, J. R. 431 - 1112 - 2068 - [Safe and Rivaroxaban for Treatment Cancer-Associated Thromboembolic Disease: of Inferior Vena Cava Filter Placement in a Large Population of Cancer Patients Diagnosed with Pulmonary Embolism: Risk for Recurrent Venous Thromboembolism, Survival, and Filter-Related Complications](Paper81545.html) 2068 - [Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Versus Low Molecular Weight Heparin for Cancer-Associated Parameswaran, R. V. 2813 - 4077 - 4084 - [Disease and Clinical Characteristics of Patients with Polycythemia Vera: An Early View of the Reveal Study](Paper78988.html) 4077 - [Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States](Paper79001.html) 4084 - [Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Parcelier, A. Pardal, E. 1508 - 3944 - [Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study](Paper80585.html) 3944 - [Incidence, Risk and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group](Paper86364.html) Pardanani, A. 350 - 354 828 1599 1611 - 2140 Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival](Paper82160.html) 354 - [ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis](Paper79969.html) 1599 - [Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia](Paper79911.html) 1611 - [Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival](Paper79665.html) 2140 - [Spectrum of Mutations Associated with Hereditary Erythrocytosis](Paper81173.html) 2801 - [Driver Mutations and Prognosis in 1118 Patients Primary Myelofibrosis](Paper80290.html) 2802 - [CD123 Immunostaining in Systemic Mastocytosis: Differential Expression Disease Subgroups and Potential Prognostic Value](Paper80182.html) 2805 - [Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices](Paper79445.html) 2819 - [Peripheral Blood JAK2V617F Quantitative Assessment in Between Allele Burden and Clinical Phenotype](Paper80177.html) 2875 - [Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment](Paper79148.html) 2882 - [ASXL1 Mutations in Myelodysplastic Syndromes with 1% Ring Prevalence, Clinical and Prognostic Relevance](Paper79622.html) 3476 - [Platelet Transmission Electron Microscopy and Flow Cytometry in the Diagnosis of Congenital/Hereditary Qualitative or Quantitative Platelet Disorders](Paper79673.html) 4062 - [Momelotinib Therapy Myelofibrosis: Survival and Genotype Correlations](Paper81686.html) 4068 - [Molecular Correlates of Anemia in Primary 4078 - [Busulfan for the Treatment of Myeloproliferative Clinic Experience](Paper85426.html) Pardee, T. 2102 - 2556 - [Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)](Paper81466.html) 2556 - [The Mitochondrial High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)](Paper79012.html) Pardo, L. 560 - 561 - [A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531](Paper81388.html) 561 - [Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531](Paper81440.html) Pardo, W. I. Pare, G. Paredes Aguilera, R. Parekh, C. Parekh, S. 342 - 840 1253 - 1434 - 1851 - 3051 - 3571 - - [Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R](Paper85773.html) 840 - [Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma](Paper85679.html) 1253 - Cooperates 1434 [CD25 (IL2RA) Orchestrates Negative Feedback Acute Lymphoblastic Leukemia](Paper86910.html) 1851 - [Patient-Specific Mutation-Derived Tumor in Multiple Myeloma](Paper83728.html) 3051 - [Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib](Paper83677.html) 3571 - [Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab](Paper83661.html) 4195 - [Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof](Paper86286.html) 4226 - [A Phase II Weekly Dexamethasone in Myeloma](Paper83530.html) Parge, M. K. 2023 - 4394 - [Moderate Reduction in LVEF Is Associated with an Increased Risk of Post-HSCT Symptomatic Cardiomyopathy](Paper82320.html) 4394 - [Smoking History and Pre-Transplant Pulmonary Function Predict Post-Transplant Respiratory Failure, Acute Renal Failure Requiring Dialysis and 100-Day Mortality in Allogeneic Bone Marrow Transplantation](Paper84023.html) Parikh, R. A. Parikh, S. A. 481 - 630 717 - 834 1014 Venous Thromboembolism in Patients with Hematologic Malignancies in United States from 1993 to 2012](Paper79928.html) 717 - [The Importance of Pharmacovigilance during Ibrutinib Therapy Chronic Lymphocytic Leukemia (CLL) in Clinical (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)](Paper84816.html) 1014 - [Analysis of Serum Ferritin Levels As a for Lymphohistiocytosis (HLH) in Hospitalized Adult Patients](Paper85232.html) 2919 Involvement By Chronic Lymphocytic Leukemia](Paper78393.html) 2926 - [Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia](Paper83271.html) 2935 - [Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice](Paper84768.html) 2950 - [Atrial Fibrillation in Patients with Chronic (CLL)](Paper82991.html) 4169 - [Pure - 3198 - [Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia](Paper86470.html) - [Association of Azacitidine Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study](Paper81566.html) 3198 - [Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients](Paper84760.html) Parizher, G. Park, A. Park, B. Park, C. J. 1220 - 3826 - 3860 - 4205 - [Identification of Novel Fusion Genes and Differentially Expressed Genes in Acute Leukemia through Transcriptome Analysis](Paper86890.html) 3826 - [Expression of JL1 Myelodysplastic Syndrome](Paper81965.html) 3860 - [Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified](Paper86677.html) 4205 - [Increased Circulating Plasma Cells Predicts Poor Overall Survival in Symptomatic Plasma Cell Myeloma Patients](Paper84286.html) Park, C. S. Park, C. Y. 306 - 481 - 781 - 1228 - - [Divergent Dynamics Function](Paper80639.html) 1228 - [Desuppressed Stem Cell Differentiation](Paper86844.html) 4101 - [Analysis of Myelodysplastic Syndrome Stem Cells at Single Cell Resolution during DNA Methyltransferase Inhibitor Therapy](Paper83310.html) Park, E. PARK, E. Park, E. Park, G. Park, H. S. 3826 - 4379 - [Expression of JL1 Antigen and Myelodysplastic Syndrome](Paper81965.html) 4379 - [Allogeneic Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia in Remission - a Prospective Comparison of Three Different Donor Groups; Matched Sibling, Matched Unrelated, and Haploidentical Family Donors](Paper81518.html) PARK, H. Park, H. Park, J. H. 449 - 682 - 1290 - 1476 - - in BRAF-Mutant Hairy Cell Leukemia](Paper86747.html) 682 - [Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL](Paper86688.html) 1290 - [Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL)](Paper86543.html) 1476 - [Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan Kettering Cancer Center](Paper82973.html) 2533 - [Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL](Paper80225.html) 2644 - [Cytogenetics in Hairy Cell Leukemia at Diagnosis and Relapse: The Rate of Therapy-Related Myeloid Malignancies Is and Patients with Untreated Acute Myeloid Leukemia (AML)](Paper81957.html) Park, J. H. Park, J. Park, J. Park, J. Park, J. S. 476 - 4053 - [Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial](Paper80347.html) 4053 - [Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib](Paper83923.html) Park, J. PARK, M. J. Park, M. J. 1380 - 2583 - [A Combination of EVI1 and PRDM16 Expression Clarified the Clinical Features of Intermediate/High Risk Patients in Pediatric Acute Myeloid Leukemia](Paper82499.html) 2583 - [High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia](Paper82428.html) Park, R. Y. Park, S. H. Park, S. K. Park, S. Park, S. N. 1233 - 1726 - 3347 - [Clonal Changes Detected By Target Capture Sequencing and Molecular Cytogenetic Study in Patients with Aplastic Anemia](Paper84127.html) 1726 - [Ethnic Difference in Genomic in Targeted Exome Sequencing and Molecular Spherocytosis By Multi-Gene Target Sequencing in Korea](Paper84229.html) Park, S. Park, S. 95 - 1665 - 1677 - 1695 - 2872 - 2881 - - [Outcome of after Failure of Lenalidomide Therapy](Paper80187.html) 1665 - [Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study](Paper80801.html) 1677 - [Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in Leukemianet EU-MDS Registry](Paper81737.html) 1695 - [Efficacy of Azacitidine (AZA) in and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) Patients Treated Hypomethylating Agents (HMA): A Report By the GFM](Paper81092.html) 2881 - [MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM](Paper80406.html) 2892 - [A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)](Paper78549.html) 2893 - [Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA)](Paper81314.html) Park, S. I. Park, S. I. Park, S. M. Park, S. W. Park, Y. S. Park, Y. Parker, A. Parker, C. A. Parker, C. J. Parker, E. 123 - 1066 - 3491 - [Bioengineering Coagulation Factor VIII through Ancestral Protein Reconstruction](Paper86874.html) 1066 - [Anti-C1 Domain Antibodies Are Pathogenic in a Murine Tail Snip Model Despite Low Inhibitor Titers](Paper81126.html) and Epitope Specificity of Antibodies in Acquired and Hereditary Hemophilia Inhibitor Patient Plasma](Paper84730.html) Parker, G. S. Parker, H. Parker, M. Parker, P. M. Parker, R. E. Parker, T. L. Parker, W. T. Parker, W. T. 475 - 600 - 2777 - [Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression](Paper82229.html) 600 - [High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis](Paper79711.html) 2777 - [BCR-ABL Assay Sensitivity of MR4.5 Achieved and MR5 >75% of Samples, through mRNA Selection before qRT-PCR](Paper80366.html) Parker-Thornburg, J. Parkin, B. 225 2909 - 3838 - [High-Sensitivity Genomic Minimal Residual Disease Detection Reveals Multiclonal Hematopoiesis and Is Associated with Survival in Adult AML](Paper80789.html) 1907 - [Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies](Paper84005.html) 2095 - [The Impact of Diabetes on Clinical Outcomes in Chronic Lymphocytic Leukemia](Paper85181.html) 2909 - [A Quantitative Analysis of Subclonal and Clonal Gene Mutations Occurring Pre- and Post-Therapy in 53 Cases of Chronic Lymphocytic Leukemia](Paper80712.html) 3838 - 2069 - [Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study](Paper84937.html) 2069 - [A Systematic Review of the Classification, Diagnosis, Treatment and Outcome of Osteonecrosis of the Hips in Sickle Cell Disease](Paper86568.html) Parmar, D. V. Parmar, G. Parmar, K. Parmar, 929 - 3704 - [Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial](Paper83176.html) 929 - [Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study](Paper83303.html) 1190 - [Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Following Reduced Intensity Conditioning Regimens](Paper78284.html) 1269 - [Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase sAML Cells](Paper87052.html) 3194 - [Outcome of Multiple Myeloma Compared to IgG/IgA Myeloma after Mantle Cell Lymphoma (MCL) Cells](Paper84280.html) Parmigiani, G. 504 - 726 - 835 - 837 - 2420 - 2989 - 4212 - [Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition](Paper84039.html) 726 - [Functional and Clinical Impact of Splicing Factor Dysregulation in Multiple Myeloma](Paper85092.html) 835 - [The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact](Paper85084.html) 837 - [Redefining Mutational Profiling Using RNA-Seq: Insight into the Functional Mutational Landscape of Multiple Myeloma](Paper85933.html) 2420 - [Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance](Paper85919.html) 2989 - [Differentially Expressed and Prognostically Significant Lincrnas May Impact Immune System and Tumor Progression in Multiple Myeloma (MM)](Paper84866.html) 4212 - [Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)](Paper85493.html) Parnell, J. Parody, R. 3142 4363 International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Globulin - 2646 - 2708 - [The Results of the Russian Clinical Trial of Mesenchymal Stromal Cells (MSCs) in Severe Neutropenic Patients (pts) with Shock (SS) (RUMCESS trial)](Paper79099.html) 2497 - [Absence of High-Dose Consolidation Courses and Low Numbers of Allogeneic HSCTs Did Not Affect Overall Optimistic Results in B-Cell Precursor Ph-Negative Adult ALL Patients Treated By Non-Intensive but Non-Interruptive ALL-2009 Protocol: Data of the Group](Paper79799.html) 2646 - [The Secretion of Paraprotein Is Associated with Bone Marrow Involvement in Patients with Diffuse Large B-Cell Lymphoma](Paper82714.html) 2708 - [Addition of R-HMA to R-DA-EPOCH Favourably Changes the Outcome in Patients with Untreated High-Grade Diffuse Large B-Cell Lymphoma: The First Results of Russian Prospective Multicenter Parrens, BCL2 and Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075](Paper86240.html) Parrinello, N. L. Parrish, C. 394 - 1981 - 3180 - [A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial](Paper81198.html) 1981 - [Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial](Paper84484.html) 3180 - [Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience](Paper84463.html) Parrott, T. Parsons, A. 867 - 2462 - 3006 - [JAK1/2 Protection of AML](Paper84426.html) 2462 - [BCL2-Inhibitors Target a Major Group of Newly-Diagnosed Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo](Paper82622.html) 3006 - [Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease](Paper84640.html) Parsons, B. Parsons, C. Parsons, D. W. Parsons, S. K. 2635 - 2636 - [An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy](Paper82912.html) 2636 - [Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group [Fludarabine Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing](Paper79843.html) 3210 - [Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes](Paper79877.html) 4370 - [The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly](Paper79326.html) Partanen, A. Parthan, Pasarolls, F. Paschal, C. R. Paschka, P. 85 - 224 - 226 - 227 - 322 - 803 - 1381 - 2585 - 2586 - 3818 - 3844 - 4123 - [Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data](Paper84855.html) 224 - [Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis](Paper81579.html) 226 - [Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)](Paper80987.html) 227 - [Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)](Paper82670.html) 322 - [Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606)](Paper83735.html) 803 [Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML](Paper82044.html) 1381 - [Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML)](Paper82599.html) 2585 - [Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3-ITD Positive AML Patients within the AMLSG 16-10 Trial: A of the AML Study Group 2586 - [Molecular Characterization 3818 - of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study (AMLSG)](Paper80404.html) 4123 - [Sequential Molecular Characterization Based Delineation of Potential Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome](Paper85736.html) Paschon, D. E. Pasciuta, R. Pascual, C. Pascual, M. J. Pasero, P. Pasha, R. Pashayeva, K. Pasi, K. J. 290 - 547 - 551 - 1087 - 1088 - 2307 - - [Modification Inhibitor Risk in Hemophilia-a Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B](Paper79762.html) 1087 - [Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE](Paper79266.html) 1088 - [Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study](Paper79296.html) 2307 - [Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and 3520 - [Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A](Paper79141.html) Pasker- de Jong, P. C. Pasquali, F. Pasquini, M. C. 61 - 198 - 397 - 2621 - [Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study)](Paper80661.html) 198 - [Allogeneic Stem / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)](Paper85621.html) 397 - [Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study)](Paper82231.html) 2621 - [Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT)](Paper80724.html) Pasquini, M. C. Passamonti, F. 4055 - 4073 - [Practice-Relevant Revision Patients with WHO-Defined Essential Thrombocythemia](Paper79053.html) 4073 - [Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)](Paper80959.html) 4080 - [Symptom Burden Profile with Thrombocytopenia: Lessons and Unmet Needs](Paper78903.html) Passamonti, F. 351 - 827 - 4060 - 4071 - [Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group [An Open-Label, Multicenter, Dose-Finding, Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study](Paper83201.html) 4060 - [Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)](Paper80790.html) 4071 - [Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study 596 of the Registro C. 2737 - 2753 - [Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression](Paper83673.html) 2753 - [The Proteasome Inhibitor, Ixazomib, Combined with in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach](Paper83032.html) Passweg, J. 153 - 3202 - 4364 - [Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)](Paper82068.html) 3202 - [Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT](Paper82086.html) 4364 - [Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)](Paper81982.html) Passweg, J. R. 3209 - 4397 - [Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis](Paper79571.html) 4397 - [Very Good Response and Overall Survival after Allogeneic Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis; Results of a Non-Interventional Study By the Plasma Cell Disorder Subcommittee of the Chronic Malignancy Working Party of the EBMT](Paper84953.html) Pastan, I. 1332 - 4161 - [Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design](Paper80180.html) 4161 - [High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome](Paper82492.html) Pastano, R. Pastor Loyola, V. B. Pastore, A. Pastore, A. 302 - 571 - [ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis](Paper85816.html) 571 - [Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy](Paper86438.html) Pastore, D. Pastore, F. - 2416 - 3337 - [A Systematic Review of the Classification, Diagnosis, Treatment and Outcome of Osteonecrosis of the Hips in Sickle Cell Disease](Paper86568.html) 2136 - [The Phenotypic Spectrum of Pyruvate from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status](Paper80702.html) 2416 - [Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes](Paper84100.html) 3337 - [Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of New Variants](Paper80864.html) Pastori, G. Pasvolsky, O. Patarroyo-White, S. Patay, B. Patch, T. Patee, G. Patel, A. Patel, A. Patel, B. J. 86 - 300 - 607 - 608 - 611 - 1319 - 1405 - 3788 - [The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML)](Paper83477.html) 300 - [Impact of Eltrombopag on Expansion Clones Somatic Mutations Refractory Aplastic Anemia](Paper86231.html) Prognostic Scoring System \"Molecular\" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS)](Paper83638.html) 608 - [The 611 of Syndromes](Paper82710.html) of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 [Whole-Exome Sequencing - [TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition](Paper83115.html) 1652 - [Myelodysplastic Syndrome (MDS)-Determining Clonal Anemia (AA)](Paper86185.html) 2216 - [Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia](Paper85057.html) 2848 - [Determinants of Phenotypic Commitment and Clonal from the of Clonal Architecture in CMML](Paper86610.html) 3788 - [Ex Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used As Adjuvants to Regular Chemotherapy in IDH1/2-Mutated Acute Myeloid Leukemia](Paper86972.html) Patel, C. Patel, C. Patel, D. Patel, J. Patel, J. L. Patel, J. M. Patel, J. P. 2331 - 2334 - 2335 - [Patients Prescribed Warfarin with Poor Time in Therapeutic Range (TTR) Have Different Beliefs about Their Illness and Anticoagulation Therapy Compared to Those with a Good TTR - Early Results from the Switching Study](Paper80129.html) 2334 - [Rivaroxaban-Mediated Vascular Relaxation As a Potential Cause of Headaches and Dizziness](Paper80791.html) 2335 - [Do the Safety and Efficacy Outcomes Reported in the Clinical Trials of Direct Oral Anticoagulants (DOAC) Translate to the Real-World?](Paper81914.html) Patel, K. B. Patel, K. P. 60 - 564 - 598 - 1392 - 1681 - 1703 - 1730 - 2700 - 3746 - 3756 - 3828 - [Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study](Paper82371.html) 564 - [Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia](Paper79629.html) 598 - [Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities](Paper80360.html) 1392 - [Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups](Paper84207.html) 1681 - [TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53](Paper87154.html) 1703 - [Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R](Paper85687.html) 1730 - [RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia](Paper85908.html) 2700 - [Clinico-Pathological Characteristics, Treatments and Outcomes of Dendritic Single-Center Experience: of Clinical and Molecular Characteristics and Patient Outcomes](Paper86608.html) 3756 - [Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia](Paper80667.html) 3828 - [Prognostic Impact of Kinase Mutations and Minimal Residual Disease in Core-Binding Factor Leukemia](Paper82206.html) Patel, K. K. 929 - 2011 - 3136 - 3192 - 4376 - [Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study](Paper83303.html) 2011 - [Bfr fludarabine, (CLL).](Paper79916.html) 3136 - [Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit](Paper85991.html) 3192 - [In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined of 3 Trials](Paper84093.html) 4376 - [Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results](Paper80837.html) Patel, M. I. Patel, M. R. 257 - 323 - 3928 - 3929 - 4154 - [Phase 1 Trial Testing Single Agent a Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma](Paper81310.html) 323 - [Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial](Paper81999.html) of Duvelisib Leukemia](Paper82074.html) 3929 - [Clinical and Correlative Results of a 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies](Paper79625.html) 4154 - [TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma](Paper83473.html) Patel, M. Patel, M. 1485 - 4061 - 4257 - [High-Depth, Targeted, Next Generation Identifies in Cutaneous T-Cell Lymphoma](Paper85911.html) 4061 - [Targeted Sequencing Reveals Clinical Phenotype in MPNs](Paper86820.html) 4257 - [Biomarkers of Cardiotoxicity Patients Subsequently Treated with Proteasome Inhibitor Therapy](Paper84164.html) Patel, M. Patel, M. Patel, M. Patel, M. Patel, N. Patel, N. Patel, P. R. Patel, P. Patel, P. 3300 - 4451 - 4466 - 4486 - [Long Term Trends in Chronic Myeloid Leukemia (CML) Following the FDA Approval of Tyrosine Kinase Inhibitors (TKIs), on Bone Marrow Transplant Rates and Clinical Outcomes - a Study of the Nationwide Inpatient Sample Between 1998-2011](Paper86386.html) 4451 - [The Impact of Winter Months on Patients with Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), a Retrospective Analysis of Hospital Outcomes in the United States (US) from 1998-2011](Paper86615.html) 4466 - [Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant](Paper80735.html) 4486 - [Cost of Leukemia Comparison to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Based on the Nationwide Inpatient Sample (NIS) Database from 2002 to 2011](Paper86236.html) Patel, P. R. 1998 - 2053 - 4271 - [Melphalan 200 Mg/m2 in Patients with Renal Impairment Is Associated with Increased Short Term Toxicity but Improved Response and Longer Treatment-Free Survival](Paper84115.html) 2053 - [Dual DNA Damage Repair for Myeloma and Acute Leukemia](Paper86477.html) 4271 - [Preclinical Study for the Use of Abatacept to Prevent Rejection of Allogeneic CD34+ Cells in a Xenograft Model](Paper85346.html) Patel, P. P. Patel, R. K. 2331 - 2335 - 3550 - [Patients Prescribed Warfarin with Poor Time in Therapeutic Range (TTR) Have Different Beliefs about Their Illness and Anticoagulation Therapy Compared to Those with a Good TTR - Early Results from the Switching Study](Paper80129.html) 2335 - [Do the Safety and Efficacy Outcomes Reported in the Clinical Trials of Direct Oral Anticoagulants (DOAC) Translate to the Real-World?](Paper81914.html) 3550 - [Screening for Occult Malignancy Following First Unprovoked VTE: A Single Centre Experience](Paper82176.html) Patel, R. Patel, S. Patel, S. Patel, S. Patel, S. B. Patel, Y. B. Patel, Z. Patel-Donnelly, D. 587 - 814 - [Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study](Paper79176.html) 814 - [Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study](Paper78901.html) Paterson, A. D. Pathak, R. 533 - 2076 - 3272 - [Overall Survival (OS) of Acute Myeloid Leukemia (AML) Treated at Academic Center (AC) Versus Non-Academic Center (NAC)](Paper86876.html) 2076 - [Prevalence of Pulmonary Embolism Among Patients with Acute Exacerbations of Chronic Obstructive Pulmonary: Data from Nationwide Inpatient Sample](Paper86927.html) 3272 - [Medical and Economic Burden of from the National Inpatient Sample K. 2582 - 2615 - [Plasmacytoid Dendritic Cell Burden in the Bone Marrow Predicts End of Induction Minimal Residual Disease Status in Adult Acute Myeloid Leukemia](Paper82355.html) 2615 - [An Integrated Genomic Classification That Includes Copy Number Alterations Is Highly Predictive of Post Induction Minimal Residual Disease (MRD) Status in Childhood Precursor B Lineage Acute Lymphoblastic Leukemia](Paper80382.html) Patkowska, E. Patmore, R. Patnaik, A. Patnaik, M. M. 55 - 453 - 736 - 951 - 1013 - 1913 - 1923 - 2140 - 2490 Therapy Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis](Paper79009.html) 453 - [Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)](Paper83724.html) 736 - [Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing](Paper79843.html) 951 - [Iron Deficiency Anemia Associated with Extracorporeal Photophoresis: A Retrospective Analysis](Paper84253.html) 1013 - [Incidence and Outcomes of Neutropenia in Patients Celiac Disease- Consecutive Analysis of 1729 Patients](Paper81408.html) 1913 - CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation Acute Myeloid Leukemia](Paper83592.html) 1923 - [Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation](Paper83914.html) 2140 - [Spectrum of Mutations Associated with Hereditary Erythrocytosis](Paper81173.html) 2490 - [Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis](Paper86964.html) 2563 - [Randomized Phase II Trial of Timed Arabinoside with and without the CHK1 Inhibitor Relapsed and 2864 - [Prognostic 2875 - [Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment](Paper79148.html) 2882 - [ASXL1 Mutations in Myelodysplastic Syndromes with 1% Ring Prevalence, Clinical Correlates and Prognostic Relevance](Paper79622.html) 3210 - [Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes](Paper79877.html) 3355 - [Clinico-Pathological Sideroblastic Anemias](Paper80781.html) 3476 - [Platelet Transmission Electron Microscopy and Flow Cytometry in the Diagnosis of Congenital/Hereditary Qualitative or Quantitative Platelet Disorders](Paper79673.html) 3730 - [Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients](Paper83911.html) 3747 - [Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011](Paper81710.html) 4067 - [Vascular Events and Risk Factors for Thrombosis Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T)](Paper79666.html) 4370 - [The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly](Paper79326.html) Patnaik, S. Patra, P. K. Patriarca, F. 392 - 1974 - 1999 - [Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial](Paper78741.html) 1974 - [Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79710.html) 1999 - [Benda-BEAM High-Dose Therapy Prior Patrone, L. 2299 Half-Life, (BAX 855) in Individual Procedures](Paper86419.html) 3522 - [An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX of Hemophilia a](Paper80436.html) Patsoukis, N. Patten, P. E. 363 - 615 - 1474 - 1738 - [The Correlation of APOBEC Gene Family Member Expression with Worse CLL Patient Outcome Suggests a Role in CLL Mutational Evolution](Paper81332.html) 615 - [In-Vivo Labelling Studies in Patients with Chronic Lymphocytic Leukemia Studies Demonstrate the Existence of Apparently Distinct Subpopulations That Differ in Phenotype Immune Privilege](Paper84677.html) 1738 - [CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse](Paper83578.html) Patten, P. E. Patterson, C. J. 128 - 705 - 1563 - 1833 - 2665 - 3926 - Profile, Waldenstrom's Macoglobulinemia](Paper86814.html) - [HCK Is a Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously - [Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88](Paper86491.html) 3926 - [Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS](Paper85390.html) 4004 - [Targeting Patton, N. Paty, J. Paubelle, E. Paublant, F. Pauker, S. G. Paul, H. 1742 - 1982 - 4163 - [A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)](Paper78885.html) 1982 - [Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTM\u00c2 chain (HLC) Normalization](Paper86606.html) 4163 - [An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)](Paper78883.html) Paul, J. Paul, S. Pauli, E. K. 1538 - 2942 - [Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results](Paper83926.html) 2942 - [A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in 1597 - 3645 - [REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data](Paper83161.html) 3645 - [GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment](Paper78730.html) Paulson, A. Paulson, K. Paulus, A. 703 - 1279 - 1557 - 2754 - [VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib](Paper86818.html) Identification 1328 - 3765 [A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage (B-ALL) and Highly Aggressive Ib Trial the mTOR Inhibitor Everolimus Given in with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia](Paper83337.html) 3792 - [Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Leukemia: Safety, Exposure and Target Inhibition](Paper78492.html) Paunic, Pautas, C. Pavan, J. Pavani, Allogeneic Disease](Paper83468.html) 4362 - [Standardized after Allogeneic Cross-Sectional 1-Year Evaluation in 260 Adults](Paper83770.html) 4400 - [Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients](Paper85446.html) Pavia, O. Paviglianiti, A. 3203 - 3214 - [Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Malignancies Working Party-EBMT Study](Paper78746.html) 3214 - [Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study](Paper80439.html) Pavithran, K. Pavlasova, G. Pavletic, S. Z. 64 - 65 - 99 - 145 - 922 - 1937 - 1962 - 3151 - [A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome](Paper80186.html) 65 - [Alemtuzumab-Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial](Paper82917.html) 99 - [Allogeneic T-Cells Expressing B-Cell Malignancies Hematopoietic Stem Cell Transplantation without Causing Disease](Paper81459.html) 145 - [Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Host Disease (cGVHD)](Paper85496.html) 922 - [Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease](Paper84130.html) 1937 - [Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis](Paper81740.html) 1962 - [Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation](Paper80893.html) 3151 - [Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party](Paper86372.html) Pavlick, D. Pavlovsky, A. 1739 - [Abbreviated Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience](Paper86353.html) Pavlovsky, C. 344 - 1590 - 1739 - [Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study](Paper86415.html) 1739 - [Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience](Paper86353.html) Pavlovsky, M. - (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study](Paper86415.html) 1739 - [Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience](Paper86353.html) Pavone, M. E. Pavone, V. Paw, B. H. 271 - 272 - 405 - 1165 - [Mitochondrial Protein Kinase A Regulates Heme Biosynthesis](Paper79197.html) 272 - [Biallelic Mutations in PARP4 Are Linked to a Variant Form of Congenital Dyserythropoietic Anemia](Paper82065.html) 405 - [Fam210b Is Required for Mitochondrial Iron Uptake during Erythroid Differentiation](Paper80615.html) 1165 - [Hematopoietic Stem Cells Develop in Endothelial Cadherin 5 Expression](Paper81939.html) Pawarode, A. Pawelec, Triplet Induction Therapy Approaches to Response Newly Diagnosed, Transplant Eligible, Myeloma Patients](Paper82548.html) 371 [Spatiotemporal Analysis of Intraclonal Heterogeneity in Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing](Paper81201.html) 1758 - [WB-DWI MRI Scanning Assessment of Myeloma Disease Burden](Paper78478.html) 1792 - [Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET Knock out Cell Lines](Paper85366.html) 1847 XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases](Paper82618.html) 1852 - [Velcade, Vorinostat and Dexamethasone (V2D) in Phase 2 Muk Four Trial](Paper79311.html) 2981 - [Specific Identification of High Risk Disease Using Molecular Profiling By (Myeloma of Their Relevance - an Analysis of 1,036 Myeloma Trial Patients](Paper83872.html) Paxton, C. N. 1427 - 3925 - [Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As Survival](Paper86110.html) 3925 - [Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma](Paper80530.html) Payen, E. Payne, Payne, K. Payne, G. Payne-Turner, D. Payton, J. E. Paz, P. Pazina, T. Pazolli, E. Peace, D. Peacock, W. F. 747 - 2058 - [Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database](Paper77781.html) 2058 - [Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?](Paper80234.html) Peak, D. Peale, Jr., F. V. Pearce, R. Pearsall, R. S. Pearse, R. N. 500 - 2991 [Inhibition Accelerates IKZF1 and IKZF3 Degradation](Paper83693.html) 2991 - [Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma](Paper85078.html) 4232 - [Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide Bortezomib](Paper85083.html) 4258 - [High-Dose Carfilzomib and Dexamethasone Treatment in Symptomatic Multiple Myeloma](Paper84659.html) Pearson, J. Peccatori, J. 263 - 3124 - 4335 - 4362 - 4400 - [Tracking Genetically Dynamics of T-Cell Immunological Memory](Paper82194.html) 3124 [Facing Disease](Paper83468.html) 4362 - [Standardized after Allogeneic Cross-Sectional 1-Year Evaluation in 260 Adults](Paper83770.html) 4400 - [Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients](Paper85446.html) Peccatori, J. Peelinas, V. Pechanska, P. Pecher, A. C. A. Peck, J. D. Peckham, E. Peckitt, C. Pecoraro, A. Pedersen, C. C. Pedersen, M. B. Pedersen, R. S. Pedone, M. P. Pedreo, M. Pedro, C. 608 - 1672 - 1682 - 2866 - 2894 - Mortality in the Myelodysplastic Syndromes (MDS): Study from the Spanish MDS Cooperative Group (GESMD)](Paper83226.html) 1682 - [Methylation Patterns in Patients with High-Risk Myelodysplatic Syndromes and Secondary Acute Myeloid Leukemia Treated with Azacitidine MDS 2009 and Compartment Improves the Risk Stratification of MDS with Excess of Blasts](Paper82157.html) 2905 - [Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol from CETLAM Group)](Paper79704.html) Pedro, C. 609 - 2896 - [An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)](Paper85313.html) 2896 - [A and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD](Paper82929.html) Pedro, M. C. Pedrono, E. Pedziwiatr, D. Peerschke, E. I. Peffault de la Tour, R. 1908 - 1946 - 3214 - 4367 - 4377 - [CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC](Paper80032.html) 1946 - [Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA](Paper78843.html) 3214 - [Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study](Paper80439.html) 4367 - [Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise for Patients with CD30 Anaplastic or T Cell Non Hodgkin Lymphomas: A Study on Behalf of the SFGM-TC.](Paper81210.html) Peffault de Latour, R. 153 - 1985 - 3208 - [Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)](Paper82068.html) 1985 - [Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity](Paper79536.html) 3208 - [Reduced Intensity Versus Myelo-Ablative Conditioning Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)](Paper79553.html) Peffault Delatour, R. [Automated Lentiviral Cars Using the Clinimacs Prodigy](Paper82692.html) 2046 - [First Clinical Application of Talen CAR19 T Cells in B-ALL](Paper81653.html) 4399 - [Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)](Paper85432.html) Pegourie, B. P\u00e9gourie, B. 393 - 395 - 510 - 1831 - [Bortezomib, Thalidomide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial](Paper81103.html) 395 - [Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial](Paper81900.html) 510 - [Elotuzumab Plus Bortezomib and Dexamethasone Myeloma](Paper80233.html) Peguero, E. Pehlivan, M. Pei, D. Pei, L. Pei, S. N. Peil, H. Peinert, S. Peir\u00f3, R. Pejsova, - - 3762 - [Differences in Cell of Origin (COO) Affect Outcomes in Caucasian(C) but Not in African American(AA) Patients with Diffuse Large B-Cell Lymphoma(DLBCL)](Paper87074.html) 3715 - [Multi-Institution Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma](Paper85078.html) 4232 - [Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide Bortezomib](Paper85083.html) 4258 - [High-Dose Carfilzomib A. P. Pelish, - [Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee](Paper83382.html) Pellagatti, A. Pellegrin, S. Pellegrinelli, A. 1976 - - [High Dose Chemotherapy with Autograft in First Relapse May Overcome the Poor Prognosis of Diffuse Large B-Cell Lymphoma Patients with MYC/BCL2 of a and Others Pellegrini, C. 3937 - - Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study](Paper78933.html) Pellegrino, A. 479 - 4040 - 4054 - [Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis](Paper82619.html) 4040 - [Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase](Paper82326.html) 4054 - [Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper85017.html) 3723 - [Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper81084.html) 3734 - [Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper84891.html) Pelus, L. M. Peluso, T. 1834 - 4225 - [Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone Myeloma (RRMM)](Paper80706.html) 4225 - [An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM Pemmaraju, 94 - [Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium](Paper79646.html) 461 - [Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)](Paper86000.html) 823 - [5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)](Paper86381.html) 910 - [A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Patients with (ALL) after Failure of Inotuzumab Ozogamicin](Paper81140.html) 1313 - [Prognostic Significance of Somatic Mutations in of AML in Salvage Setting: A Retrospective Analysis](Paper84248.html) 1577 - [Additional Chromosomal Abnormalities Therapy with Imatinib, Dasatinib, Nilotinib and in Patients with Newly Diagnosed Chronic Myeloid Leukemia](Paper80912.html) 1580 - [Outcomes of Patients with Chronic Phase CML Who Discontinued Ponatinib in the Frontline Setting](Paper81621.html) 1587 - [Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)](Paper85876.html) 1691 - [Efficacy and Safety of Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent A - [Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study](Paper79652.html) 2504 - [Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL)](Paper84898.html) 2508 - [Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial](Paper79648.html) 2541 - [Phase II Study of Cladribine, Idarubicin, Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia](Paper82437.html) 2579 - [Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia](Paper81432.html) 2604 - [Fusion Transcript Reduction in Core Binding Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents](Paper85811.html) 2877 Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) - [Liposomal Vincristine (Marqibo) Combined Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Single-Center Experience: of Clinical and Molecular Characteristics and Patient Outcomes](Paper86608.html) 3795 - [Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients Score for Adults with Acute Myeloid Leukemia in First Complete Remission](Paper85401.html) 4069 - [Do Patients with Post-Essential Thrombocythemia N. 2943 - 4347 - [Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy](Paper81539.html) 4347 - [Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia](Paper78557.html) Pemovska, T. 792 - 867 - Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for - BCL2 Inhibitors Protection of AML](Paper84426.html) 2462 - [BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo](Paper82622.html) Pealver, F. J. Pealver, F. J. Pearrubia, M. J. Pearrubia, M. J. Pende, D. 195 - 789 - [Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome](Paper84874.html) 789 - [Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE\u00ae Antibody Construct AMG 330](Paper83165.html) Pende, D. 1931 - 2033 - [Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): I-II Trial](Paper85451.html) 2033 - [Natural Killer (NK) Alloreactivity Seems Not to Play a Role in Preventing Leukemia Relapse in Unmanipulated Haploidentical Bone Marrow Transplantation with Post-Transplant 3773 - 4428 - [Anti-CD19 Chimeric Antigen Receptor-Modified T Cell and Lymphocytic Leukemia: Fludarabine and In Vivo of CAR-T Cells and Clinical Outcomes](Paper83401.html) 3773 - [Addition of Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia](Paper81373.html) 4428 - [Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab](Paper85708.html) Pendergrast, J. M. Pendleton, R. C. Pendurthi, U. R. 125 - 213 - 293 - 2241 - [Tissue Factor Decryption - [The Role of Putative Phosphatidylserine-Interactive Residues of Tissue Factor on Its Coagulant Activity at the Cell Surface](Paper81413.html) 293 - [Pharmacological Concentrations of Recombinant Factor VIIa Restores Hemostasis in Acquired Hemophilia Primarily Independent of Tissue Factor](Paper81434.html) 2241 - [Endothelial Cell Protein C Receptor Promotes Apoptosis in Malignant Pleural Mesothelioma Cells](Paper79851.html) Peneva, D. Peng, C. T. Peng, F. Peng, J. Peng, L. Peng, S. A. Peng, S. Peng, W. 1604 - 2813 - 4084 - [The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies](Paper79861.html) 2813 - [Disease and Clinical Characteristics of Patients with Polycythemia Vera: An Early View of the Reveal Study](Paper78988.html) 4084 - [Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study](Paper78992.html) A. Peniket, A. Penna, A. M. Pennati, J. D. Pennisi, M. V. H. Penza, peoc'H, Pepe, 956 2077 - 3367 - [Association Between Serum Ferritin and Liver Iron Concentration with Cardiac Iron in Pediatric Thalassemia Major Patients](Paper78122.html) 2077 - [A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients](Paper81179.html) 2141 - [Survival Comparability Between Thalassemia Major Patients: A Retrospective from the Myocardial Iron in Thalassemia (MIOT) Network](Paper78135.html) 2159 - [Deferiprone Has Dose-Dependent Effect on Liver Iron Concentration](Paper81168.html) 3367 - [Changes of Cardiac Iron and Function during Pregnancy in Trasfusion-Dependent Thalassemia Patients](Paper79552.html) Pepe, F. Pepys, M. E. Peragine, N. Perakis, A. Perales, M. 744 - 1930 - 2018 - 2027 - 3095 - 3231 - 4320 - 4332 - 4383 - 4392 - [The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation](Paper87078.html) 1930 - Brentuximab Vedotin Steroid Refractory Acute Graft-Vs.-Host (GVHD)](Paper81513.html) 2018 - [Safety and Efficacy of Allogeneic Hematopoetic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors](Paper81153.html) 2027 - [Prospective Evaluation of Cord Blood (CB) & Haplo-Identical Donor Availability Reveals Compromised Donor Access for Both Graft Types in Minorities and High Rates of Failure to Clear Haplo Donors in Adult Patients](Paper83311.html) 3095 - [Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies](Paper85469.html) 3231 - [Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies](Paper85412.html) 4320 - [Infection Burden of Double Stranded Viruses after CD34+ Selected, T-Cell Depleted (TCD) Hematopoietic (HCT) Dose Unfractionated Heparin (UFH) Prophylaxis Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients](Paper86482.html) 4383 - [A Prospective of in Relapsed/ Refractory [Successful A Large C. W. - 3067 - 4289 - [The Use of Eicosanoids to Enhance Donor Cell Engraftment after Utero in Utero Hematopoietic Cell Transplantation (IUHCT)](Paper84126.html) 3067 - [Mobilization Utero Hematopoietic Cell Transplantation (IUHCT)](Paper83664.html) 4289 - [Mechanisms of after Hematopoietic Cell Transplantation](Paper77601.html) Perazzelli, J. 1597 - 3645 - [REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data](Paper83161.html) 3645 - [GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment](Paper78730.html) Pereira, A. 609 - 1672 - [An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes Study from the Spanish MDS Cooperative Group (GESMD)](Paper83226.html) Pereira, B. Pereira, D. S. Pereira, I. B. Pereira, J. Pereira, M. Perera, M. Peres, M. Perez, A. R. Perez, A. L. Perez, A. Perez, A. 460 - 1352 - 1363 - 2552 - 3786 - [The Small Molecule Img-98, Potent Selective of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation of Model of AML](Paper85557.html) 1352 - [A Patient-Specific Ex (AML) Therapy](Paper86317.html) 1363 - [Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia](Paper81754.html) 2552 - [The BET Bromodomain Inhibitors Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro](Paper86460.html) 3786 - Testing Diagnosis of Platelet Disorders: A Single Center Experience](Paper79323.html) 3476 - [Platelet Transmission Electron Microscopy and Flow Cytometry in the Diagnosis of Congenital/Hereditary Qualitative or Quantitative Platelet Disorders](Paper79673.html) Perez De Oteyza, J. Perez de Oteyza, J. Perez de Oteyza, J. Perez de Oteyza, J. P\u00e9rez, E. Perez, E. Perez Garrido, R. P\u00e9rez, J. J. Perez, L. Perez, R. Perez Ronco, J. Perez, R. Perez Ruixo, J. J. 4222 - 4254 - [Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Inhibitors Population Analysis](Paper79034.html) 4254 - [Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Drugs A Quantitative Pharmacologic Perspective](Paper79092.html) Perez-Abellan, P. 3129 - [Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease](Paper82890.html) Perez-Corral, A. Perez-Ladaga, A. P\u00e9rez-Mart\u00ednez, A. P\u00e9rez-Mor\u00e1n, J. J. E. P\u00e9rez-Rus, G. Perez-Simon, J. A. 2007 - 2955 - 3142 - 4363 - 4373 - [The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma](Paper79506.html) 2955 - [Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients](Paper81697.html) 3142 - [An International Multicenter Comparative Analysis of Plus Sirolimus with or without Globulin - [Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning PerezPerez, - 3846 - 3847 - [Landscape of Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16)/CBFB-MYH11](Paper81000.html) 1371 - [Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Lacking Mutations in NPM1, CEBPA, RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome](Paper79483.html) 1373 - [BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia](Paper80967.html) 2578 - [AML with RUNX1 Wild-Type - a Distinct Subset?](Paper80954.html) 3821 - [Does Age of Patients Influence the Composition of Gene Mutations in Myeloid Neoplasms?](Paper81039.html) 3846 - [Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity?](Paper85036.html) 3847 - [Higher Percentages of Ring Sideroblasts and SF3B1 Mutations in Patients with AML Correlate with Mutations in TP53 and Adverse Cytogenetics, but Have No Independent Impact on Outcome](Paper85384.html) Peri, S. Pericole, F. V. Perilla-Glen, A. Perini, G. F. Perini, T. Perino, S. Perkins, A. C. Perkins, J. 3142 - 4382 - 4388 - [An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Globulin Are Associated with Poor Outcomes Following Allogeneic Cell Transplantation for Myelodysplastic Syndrome](Paper82375.html) 4388 Cell Transplantation Acute Myeloid Leukemia (AML) Not in First Remission](Paper83398.html) Perkins, M. R. Perkins, S. Perl, A. E. 306 - 321 - 798 - 3794 - [Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia](Paper79631.html) 321 - [Antileukemic Activity Tolerability of ASP2215 80mg and Greater in Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid a Phase 1/2, Study](Paper81249.html) 798 - [Potent Efficacy of Philadelphia Chromosome-like Acute and Perlat, A. Perna, A. Perricone, M. 1356 - 1606 - 1614 - 2600 - 4094 - [A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Novel Homeobox Transcription Gene](Paper85112.html) 1606 - [Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients](Paper84407.html) 1614 - [JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome](Paper84338.html) 2600 - [Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia](Paper85175.html) - [Crucial Factors of the Inflammatory Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Circulating CD34+ stem/Progenitor Cells](Paper82772.html) Perriello, V. Perrigoue, Perrone, G. A. Perrotta, S. 752 - 2156 - [Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study](Paper83489.html) 2156 - [Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years](Paper80641.html) Perrotti, D. 51 - 1243 - [Patients Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment](Paper82459.html) Perrotti, D. Perry, A. M. Perry, A. 2991 - 4232 - 4258 - [Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma](Paper85078.html) 4232 - [Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide Bortezomib](Paper85083.html) 4258 - [High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma](Paper84659.html) Perry, A. M. 631 - 2597 - 3753 - [The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis](Paper85250.html) 2597 - [Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia](Paper84594.html) 3753 - [Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States](Paper86562.html) Perry, C. Perry, D. J. 1083 - 1087 - 1093 - 2294 - [Perioperative Management of Hemostasis with Recombinant FIX Fc Fusion Protein in Subjects Undergoing Surgery in the B-YOND Study](Paper79168.html) 1087 - [Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE](Paper79266.html) 1093 - [Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study](Paper79305.html) 2294 - [Analysis of Target Joint Bleeding with Prophylactic Use of Recombinant Factor IX Fc Fusion Protein in Patients with Severe Hemophilia B](Paper79191.html) Perry, J. M. Perry, J. Persat, F. Perseghin, P. Persky, D. O. Perucca, S. 3150 - 4028 - [Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently and Relapse](Paper82984.html) 4028 - [Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/\u00b5l Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, - [Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients -Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group](Paper82841.html) 676 95 Patients](Paper81291.html) 1155 - [NIPA As a Novel Regulator of Aging and Stress Response of the Primitive HSC Pool](Paper83144.html) 1275 - [Identification of CXCR4 Expression By Targeted Imaging in Patients with Acute Myeloid Leukemia (AML)](Paper83531.html) 3035 - [Phase I/IIa Study of Relapsed or Refractory - [RIG-I-Induced Type I IFNs Promote Regeneration of the Intestinal Stem Cell Compartment during Tissue Damage](Paper84504.html) 3436 - [The RIG-I - [Significance of the IL-3 Receptor Beta FLT3-ITD Oncogeneic Signaling in AML](Paper83062.html) Pescosta, N. A. J. M. Pestano, L. A. Pestel, S. Peswani, N. Petain, A. Peter, B. Peter, K. Peter, N. 2517 - 3187 - [Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies](Paper84735.html) 3187 - [Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4](Paper81407.html) Peterlin, P. 1947 - 1955 - 2520 - 2899 - 3122 - 3218 - 4339 - [Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome](Paper81178.html) 1955 - [Post-Transplant Cyclophosphamide (PTCY) Vs of the Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) in Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Immune Reconstitution](Paper80063.html) 2520 - [No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Pre-Transplant Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases](Paper80438.html) 3218 - [Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients - [Post-Transplant Cyclophosphamide Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes](Paper83081.html) P\u00e9terlin, P. Peters, A. Peters, C. 541 - 2015 - [Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR](Paper79236.html) 2015 - [Risk Factors Affecting Outcome of Transplantation in Pediatric Acute Lymphoblastic Leukemia: Results of the International BFM ALL SCT Study](Paper80416.html) Peters, C. L. Peters, J. Peters, L. L. Peters, R. Peters, R. 1081 - 2269 - 2271 - 2279 - 3492 - 3517 - [Recombinant FIX/X-Bp from the Japanese Habu Snake Is a Universal Ligand for Purification of Highly Carboxylated Factor IX Variants and Factor X](Paper85767.html) 2269 - [Platelet-Targeted rFVIIa-Xten Improves to Recombinant FVIIa](Paper83490.html) 2271 - [Prolonged Half-Life and Improved Recovery of Recombinant Factor IX-XTEN Fusion Proteins in Hemophilia B Mouse Model](Paper85118.html) 2279 - [Evaluation of Enhanced in Vitro Plasma Stability of a Novel Long Acting Recombinant FVIIIFc-VWF-XTEN Fusion Protein](Paper85299.html) 3492 - [Recombinant FVIIIFc-VWF-XTEN Mice](Paper85338.html) 3517 - [Novel Approach to Study Biodistribution and Accumulation of Pegylated Recombinant Factor VIII in Haemophilia A Mice](Paper85360.html) Peters, T. Peters, T. L. Peterschmitt, M. J. Petersdorf, S. Petersen, A. Petersen, C. T. 1028 - 1877 - [Absence of Vasoactive Intestinal Peptide Signaling Significantly Enhances T Cell Survival Following MCMV Infection Via Increased Expression of Bcl-2 and Bcl-XL](Paper85698.html) 1877 - [Blocking VIP Signaling during Allogeneic Bone Marrow Transplantation Separates the Graft Versus Leukemia from Graft Versus Host Disease Activity of Donor CD8 T-Cells](Paper83853.html) Petersen, E. 3111 - 3211 - 3214 - 4373 - [Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT](Paper81265.html) 3211 - [A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT](Paper79874.html) 3214 - [Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study](Paper80439.html) 4373 - [Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen](Paper79712.html) Petersen, F. Petersen, M. J. Peterson, D. Peterson, E. A. 20 - 369 - 371 - 372 - [High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance](Paper86928.html) 369 - [Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations](Paper86652.html) in Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing](Paper81201.html) 372 - [The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM](Paper85583.html) Peterson, J. A. Peterson, K. R. 962 - 3377 - [Induction of Fetal Hemoglobin and Reduction of Disease Pathology in Sickle Cell Mice By a Synthetic Zinc Finger Gamma-Globin Activator](Paper85722.html) 3377 - [Generation of Non-Deletional Hereditary Beta-Yac Mouse Models: -175 Black HPFH and -195 Brazilian HPFH](Paper85904.html) Peterson, K. L. Peterson, L. F. Peterson, P. 273 - 1343 - 3253 Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease](Paper86954.html) 1343 - [Alvocidib Potentiates the of Retinoic Signaling](Paper87110.html) 3799 - [Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML](Paper86154.html) Peterson, T. J. Petillon, M. O. Petit, A. Petit, E. Petit, L. Petkova-Kirova, P. Petras, E. Petrella, T. Petrescu, C. Petrich, A. M. Petrich, A. M. 1500 - 2696 - 2737 - 3990 - [Risk Factors for Treated B Cell Non-Hodgkin Lymphomas Experience Poor Survival Outcomes and May Benefit from Intensive Induction Therapy](Paper84038.html) 2737 - [Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression](Paper83673.html) 3990 - [Selective MEK Inhibition Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial](Paper84066.html) Petricoin, E. F. Petrie, K. R. Petrillo, S. Petrini, M. Petris, M. G. Petriv, O. Petro, Petroccione, Petroff, D. Petrogiannis-Haliotis, T. Petropoulos, D. Petrou, M. Petrov, L. 479 - 4054 - [Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis](Paper82619.html) 4054 - [Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st P. Petrova, P. S. Petrowski, K. A. Petrucci, M. T. 392 - 927 - 1760 - 1974 - 2085 - [Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial](Paper78741.html) 927 - [Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79550.html) 1760 - [Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study](Paper79067.html) 1974 - [Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79710.html) 2085 - [Health-Related Quality of Life in Treated Patients with Relapsed/Refractory Multiple Petry, J. Petti, A. Pettitt, A. R. Pettitt, J. Petty, N. 372 - 724 - 1997 - 2979 - 3181 - [The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of [Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma](Paper80183.html) 1997 Autologous Transplantation Treatment-Related AML MDS Treated Multiple Myeloma Patients (pts)](Paper81194.html) 2979 - [Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma](Paper83760.html) 3181 - [A Prognostic 51-Gene Signature Linked to Benefit Added Bortezomib, Thalidomide P. Peyton, J. D. Peyvandi, F. Pezzi, A. 24 - 927 - 1968 - 2961 - [An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival](Paper79819.html) 927 - [Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79550.html) 1968 - [Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma](Paper81857.html) 2961 - [The Alternate Activation of Hedgehog Pathway, Either in CD138+ or in CD138-CD19+ Multiple Myeloma Primary Cells, Impacts on Disease Outcome](Paper80482.html) Pfannes, K. Pfeifer, D. 146 - 2432 - 3593 3834 - [Recipient Dendritic Cells By during Acute GvHD](Paper80499.html) 2432 - [Combination HDAC Inhibitors: Target Activates Canonical Signaling within the Niche Leading to Myeloproliferation, Stem Cell Exhaustion and Accelerates JAK2V617F Driven Disease](Paper77900.html) Architecture Sequencing-Identified in the Protein Tyrosine Phosphatase Ptprt and Genes](Paper83229.html) Pfeiffer, B. J. 2515 - 3742 - [Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data](Paper80563.html) 3742 - [Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?](Paper81151.html) Pfirrmann, 2517 - 2773 - 4047 - [The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia](Paper80036.html) 1581 - [Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA](Paper84570.html) 2517 - [Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies](Paper84735.html) 2773 - [Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials](Paper79760.html) 4047 - [Smoking Is a Prognostic Factor for Survival in Chronic Myeloid Leukemia](Paper82575.html) Pflug, N. Pfreundschuh, M. 27 3187 - 3922 - [Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial](Paper79113.html) 1509 - [Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R- CHOP](Paper81142.html) 2773 - [Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials](Paper79760.html) 3187 - [Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4](Paper81407.html) 3922 - [Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma](Paper85592.html) Pfreundschuh, M. 1817 - 2685 - 2734 - B Cells from Patients with MGUS and Multiple Myeloma (MM) Can Be Stimulated by Paraprotein-Target Specific T-Helper Cells to Produce Paraprotein-Identical Monoclonal Antibodies: Rationale for PARs, a Novel Therapeutic Approach with Ultimate Specificity in MGUS/MM](Paper84832.html) 2685 - [LRPAP1 Is a Frequent B-Cell Receptor - [Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients -Results of the Dense-R-CHOEP Trial of the antigens for reverse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms](Paper82531.html) Phaik Har Lim, K. Pham, A. D. Pham, Q. Pham, H. P. Pham, Pham, of Antibodies on Response of Immune Thrombocytopenia Patients to Thrombopoietin Agonists and - Anemia, Ineffective Erythropoiesis, and in 5q- Mice and Effect of Exogenous Transferrin](Paper85082.html) Phan, A. T. Phelan, D. Phelan, R. Phelps, A. Phelps, C. 1732 - 2936 - 2938 - [Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic 2936 - [Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 of Ibrutinib Combined with Bendamustine/Rituximab](Paper79007.html) 2938 - [Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)](Paper80701.html) Philip, B. Philip, C. C. Philip, C. C. 3753 - 4315 - [Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States](Paper86562.html) 4315 - [Comparable Results with Treosulfan Based Conditioning Regimen in Matched Related and Matched Unrelated Donor Transplants for Beta Thalassemia Major and the Challenges from India: A Single Center Experience](Paper83030.html) Philip, S. Philip, V. Philipp-Abbrederis, K. Philipp\u00e9, J. Philippe, L. Philippe, R. Philips, A. V. Philipsen, S. Phillips, A. Phillips, D. C. Phillips, D. Phillips, J. D. Phillips, K. L. Phillips, M. Phillips, S. E. Phillips, T. Phillis, S. Philpott, A. Philpott, C. C. Phipps, C. Phipps, J. P. Phipps, R. P. Phomoonna, T. Phong, K. T. Phung, S. Phylipsen, M. Piard, N. Piazza, F. Piazza, R. Picard, V. Picardi, A. 2004 - 3230 - 4368 - 4384 - [Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia](Paper79242.html) 3230 - [Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia](Paper85085.html) 4368 - [Haploidentical, G-CSF Primed, Unmanipulated Bone Marrow Anti-CD25 Monoclonal Antibody As Part of the Gvhd Prophylaxis for Patients with High-Risk Acute Myeloid of GvHD and Other Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission](Paper82785.html) Picardi, M. Picardi, P. Picardi, P. Picavet, D. I. P. P. 329 - 1675 - 3868 - [Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML](Paper82440.html) 1675 - [Prognostic Impact of TS, MTHFR Patients with Myelodysplastic Syndromes](Paper83190.html) 3868 - [IGH-FR1 and Leader Analysis By Next Generation Sequencing for the Detection of Clonality and 3 2165 - 2187 - 3267 - 3379 - [TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia](Paper79359.html) 2165 - [Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia](Paper77675.html) 2187 - [Hydroxyurea Shows Clinical Benefit without Alteration of Fetal Hemoglobin, MCV, or Hemoglobin in Unselected Adult and Pediatric Patients with Sickle Cell Anemia](Paper86983.html) 3267 - [Acute Care in the Emergency Department Differs before and after Transition for Adolescents and Young Adults with Sickle Cell Disease](Paper79425.html) 3379 - [Point-of-Care Screening for Sickle Cell Disease By a Mobile Micro-Electrophoresis Platform](Paper86825.html) Pichardo, J. D. 1785 - 2668 - 3655 - [Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma](Paper84149.html) 2668 - [Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay](Paper79044.html) 3655 - [Distinctive Genomic Alterations Pichiorri, F. - 1814 - 1835 - [Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development](Paper85300.html) 1814 Markers](Paper82951.html) 1835 - Myeloma Patients](Paper80924.html) Pichler, A. 2515 - 3742 - [Azacitidine in Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data](Paper80563.html) 3742 - [Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?](Paper81151.html) Piciocchi, A. 66 - 81 - 1410 - 1675 - 2946 - 3230 - [Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the Study](Paper79705.html) 81 - [Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification](Paper84424.html) 1410 - [Rapid Identification of BCR/ABL1-like Leukemia (ALL) Cases By Quantitative Real Time-PCR (Q-RT-PCR). Generation and Validation of a Predictive Statistical [Prognostic Impact of TS, MTHFR Ofatumumab (FC-O2) As Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study](Paper81042.html) 3230 - [Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia](Paper85085.html) Pickert, D. Pickles, T. Picornell, A. Picquenot, J. M. Pidala, J. A. 857 - - 3142 - 4286 - [Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations](Paper85669.html) 2113 - [Body Composition Transplantation (HSCT) Recipients](Paper83220.html) 3142 Multicenter Comparative Analysis of Plus Sirolimus with or without Globulin to Pidcoke, H. F. E. Piekarz, R. 2705 - 2731 - [Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas](Paper86837.html) 2731 - [Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor Allogeneic Disease](Paper83468.html) 4362 - [Standardized after Allogeneic Cross-Sectional 1-Year Evaluation in 260 Adults](Paper83770.html) 4400 - [Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients](Paper85446.html) Pienkowska-Grela, B. Pierce, G. F. 1087 - 1088 - 1093 - 3239 - [Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE](Paper79266.html) 1088 - [Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study](Paper79296.html) 1093 - [Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study](Paper79305.html) 3239 - [Human Factor VIII Expression and Normalization of Bleeding Following AAV Gene Therapy in a Double Knockout Mouse Model of Hemophilia](Paper86707.html) Pierce, H. Pierce, R. M. Pierce, S. 461 - 564 - 823 - 1418 I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)](Paper86000.html) 564 Acute Leukemia](Paper79629.html) 823 - [5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms 1418 - [Early [Additional Chromosomal Abnormalities Therapy with Imatinib, Dasatinib, Nilotinib and in Patients with Newly Diagnosed Chronic Myeloid Leukemia](Paper80912.html) 1587 - [Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)](Paper85876.html) 1663 - [Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS](Paper86683.html) 1681 - [TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53](Paper87154.html) 1705 - [Impact of Hypomethylating Chromosome 3 Abnormalities](Paper86434.html) 2503 - [Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse](Paper84880.html) 2504 - [Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL)](Paper84898.html) 2508 - [Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial](Paper79648.html) 2579 - [Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia](Paper81432.html) 2796 - [Seven Year Follow up of Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib 400 Mg Twice Daily - a Single Center Study at MDACC](Paper86559.html) 3718 - [Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure](Paper85683.html) 3722 - [Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Single-Center Experience: of Clinical and Molecular Characteristics and Patient Outcomes](Paper86608.html) 3756 - [Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia](Paper80667.html) 3776 - [Long Term Outcome of Patients with Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, with Refractory or Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)](Paper84781.html) 3850 - [Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission](Paper85401.html) 4069 - [Do Patients with Post-Essential Thrombocythemia from with Primary Myelofibrosis?](Paper84282.html) Pierceall, W. E. Pierdomenico, F. Pieri, L. 351 - 353 - 825 - 1615 - 1630 - 2803 - 4087 - [Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients](Paper80206.html) 353 - [Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors](Paper81593.html) 825 - [Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis](Paper81430.html) 1615 - [IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers](Paper81040.html) 2803 - [Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative 4087 - of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study](Paper81061.html) Pierini, A. A. 1876 - 1885 [Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Transplantation](Paper78902.html) - [TNF-Alpha Enhances CD4+FoxP3+ in GvHD Prevention and Treatment](Paper83636.html) 4284 - [Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility 4071 - [A Novel Lethal Targeting SIRT6 in Acute Myeloid Leukemia](Paper81338.html) 2122 - [Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Patients](Paper80067.html) 2775 - [Imatinib Months](Paper80130.html) 4046 - [Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial](Paper82672.html) 4071 - [Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study 596 of the Registro - 3735 - [A Double Blind Randomised Clinical Trial to Prevent Serious Side Effects of Dexamethasone during Pediatric Acute Lymphoblastic Leukemia Treatment](Paper78937.html) 2564 - [A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of - [Clinical Relevance of Pediatric BCR-ABL1-like Acute Lymphoblastic Leukemia](Paper78263.html) Pieters, R. 247 - 445 - 869 - 1237 - 1293 - 1297 - 1409 - 2423 - 2598 - [Genetic Architecture of Relapsed Pediatric B Cell Precursor Acute Lymphoblastic Leukemia Are Related to the Intensity of Upfront Therapy](Paper81013.html) 445 - [T-Cell Acute Lymphoblastic Leukemia Patients with Mutations in IL7Ra or Downstream RAS-MEK or PI3K-AKT Can be Collectively Targeted By Combination of RAS and AKT Inhibitors](Paper80143.html) 869 - [3D Modeling of Novel Transforming JAK Mutations in T-Cell Acute Lymphoblastic Leukemia Reveals Altered Pseudokinase-Kinase Domain Interactions That in Lymphoblastic Leukemia](Paper80031.html) 1293 - Molecule of LARG/RhoA B-Cell Acute Lymphoblastic Leukemia](Paper85813.html) 1297 - [B-Cell Precursor Acute Lymphoblastic Leukemia Cells a Self-Reinforcing Niche Independent of the CXCR4/CXCL12 Axis](Paper81006.html) 1409 - [Identification of FLT3 Is a Factor in Infants with MLL-Rearranged Acute Lymphoblastic or LMO2 in CD34+ HSCs Blocks the in Vitro Differentiation before the T-Cell Commitment Point and Could be Oncogenic in Early T-Cell Progenitor ALL](Paper80138.html) 2598 - [Prognostic in Pediatric Acute Megakaryoblastic Leukemia](Paper84577.html) Pietra, D. 351 - 606 - 1626 - 2830 - 4088 - 4093 - [Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients](Paper80206.html) 606 - [Whole Exome Sequencing Identifies Novel Leukemia](Paper84567.html) 1678 - [SF3B1 Mutation Is an Independent Predictor Parenchymal Iron Overload in Myelodysplastic Syndromes](Paper82887.html) 2830 - [Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis](Paper80200.html) 4088 - [Common Variation - [Fusion Gene Detection Whole Transcriptome Analysis in Patients with Chronic Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia](Paper84620.html) A. Pietsch, C. Piette, C. Piety, Piga, A. 752 - 2155 - [Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study](Paper83489.html) 2155 - [Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with and Deferoxamine- Extension Cordelia - [Prognostic Relevance Recurrent Aberrations in Pediatric Acute Megakaryoblastic Leukemia](Paper84577.html) 2622 - [Clonal Evolution and Lack of BCR-ABL1 Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment](Paper81015.html) 3664 - [Characterizing the Function of RNA Binding Protein, IGF2BP3, in Hematopoiesis](Paper83672.html) 3845 - [Clinical and Biological Characterization of Children with FLT3ITD Mutated Acute Myeloid Leukemia (AML): A Report from the AIEOP AML-2002 Study Group](Paper85031.html) Pighi, C. Pigneux, A. 218 - 451 - 1936 - 1946 - 2560 - 3736 - 3787 - [Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results 00932412)](Paper81031.html) 451 - [Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group](Paper78542.html) 1936 - [Comparable Immune Reconstitution Between Ex Vivo and Un-Manipulated Umbilical Cord Blood Transplantation](Paper79595.html) 1946 - [Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA](Paper78843.html) 2560 - [Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Lomustine Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial](Paper79405.html) 3787 - [Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly ( 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial](Paper81191.html) Pignon, J. M. G. [Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Have Survival Following Autologous Stem Cell Transplantation](Paper83188.html) 3156 - [Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation](Paper83825.html) Pika, T. Pika, T. 30 - 729 - 1844 - [Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)](Paper82083.html) 729 - [Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)](Paper81814.html) 1844 - [Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup](Paper82133.html) Pike, A. Pikman, Y. 443 - 2488 - Leukemia](Paper86220.html) 3674 Ib Trial Everolimus Given in with Multiagent Chemotherapy in Acute Lymphoblastic Leukemia](Paper83337.html) Pilarski, L. V. Pillai, M. Pillai, G. L. V. S. Pillon, M. 621 - 2305 - [Hematopoietic Stem Cell Transplantation for Hemophagocytic Lymphohistiocitosis : A National Retrospective Analysis of Data from the Italian Association of Pediatric Hematology Oncology (AIEOP)](Paper85574.html) 2305 - [Could Hemorrhagic Identified By Coagulative Tests Using Fibtem and Antithrombin Levels? A Single Pimanda, J. E. Pimentel, H. Pimentel, P. Piana, J. 582 - 2007 - 3142 - [Evaluation of the Regimen Brentuximab Vedotin in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)](Paper81925.html) 2007 - [The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma](Paper79506.html) 3142 - [An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Globulin Transplantation](Paper81828.html) Piana, L. T. L. Pine, A. B. Pineault, N. Pineda, A. Pineda, G. Pinegina, O. N. Pinello, L. Ping, C. J. Ping, J. Ping, L. Ping, N. Ping, Z. Pingali, S. R. 3169 - 4360 - [Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)](Paper84095.html) 4360 - [Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Pingel, J. Pinilla-Ibarz, J. 480 - 1575 - 2941 - 2945 - 4025 - [The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation](Paper84244.html) 1575 - [Dasatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Persistent, Low-Grade Nonhematologic Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial](Paper86560.html) 2945 - [Outcomes of Patients with Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience](Paper86445.html) 4025 - [Efficacy and Safety of Ponatinib Prior Tyrosine G. S. Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development](Paper84860.html) Pinnix, C. C. 1511 - 1980 - 3865 - Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients](Paper81696.html) - [Prospective Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM](Paper83730.html) 3865 - [Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration](Paper80902.html) Pintilie, M. Pinto, 2481 - 2704 - [Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the (MM-020) Trial](Paper81093.html) 1541 [Lenalidomide Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Study](Paper84956.html) 2479 - [Continuous (BDM) Results in of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones](Paper84797.html) 2704 - [CC-122 Expands Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma](Paper85948.html) Pinto, D. Pinto, M. R. S. Pinto, V. Pinyol, M. Pinzur, L. Pioltelli, M. L. Pipe, S. Pique, C. Piras, F. 654 - 766 - [Measurement of Thrombin Generation Is a Positive Predictive Biomarker of Venous Thromboembolism (VTE) in Metastatic Cancer the Hypercan Study](Paper81237.html) 766 - [Platelet Adhesion Under Flow Condition in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV): Analysis According to the Status](Paper84822.html) Piris, M. A. A. Pirola, A. Pirruccello, S. Pirsl, F. 65 - 1937 - [Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial](Paper82917.html) 1937 - [Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis](Paper81740.html) Pistikopoulos, E. N. Pistoia, V. Piszcz, J. Pitard, V. Pitcher, B. 334 - 337 - 471 - 578 - 2741 - PD1 Tumor-Infiltrating Lymphocytes Follicular Lymphoma Receiving Rituximab-Based Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Lymphoma Previously Untreated Follicular Lymphoma (Alliance 051103)](Paper83195.html) 578 - [Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)](Paper79261.html) 2741 - [Phase 1962 - 2637 - [Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma](Paper85044.html) 1962 - [Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression Allogeneic Hematopoietic Stem Cell Transformation: Morphology, EBV Status, Clonality and Survival Analysis a Retrospective Study of 77 Patients](Paper82284.html) Pittari, V. Pittman, D. Pivetti, C. Pivot, C. Piya, S. Piza Rodriguez, G. 1982 - [Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTM\u00c2 chain (HLC) Normalization](Paper86606.html) Pizarro, R. D. J. A. E. 1292 - 2488 - 3765 - [Bacillus Infection Among Children with Hematologic Malignancy, a Single Institution Experience](Paper85101.html) 2488 - [Synergistic Drug Everolimus Given in with Multiagent Chemotherapy Acute Lymphoblastic Leukemia](Paper83337.html) Pladna, K. Plaimauer, B. Plair, T. A. Plantaz, D. 3723 - 3734 - [Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper81084.html) 3734 - [Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper84891.html) Plas, D. Plass, C. Plass, C. 2436 - 2917 - [Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia](Paper85403.html) 2917 - [IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA IL-10 Locus](Paper84848.html) Plasse, T. Plastaras, - 2492 - 3734 - [t(12;21)/ETV6-RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and of EORTC Children 2492 [Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper85017.html) 3734 - [Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper84891.html) Platt, R. Platzbecker, U. Platzbecker, U. 92 - 95 - 222 - 356 - 386 - 609 - 912 - 1408 - 1661 - 1669 - 2099 - 3817 - 4390 - [Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study](Paper83535.html) 95 - [Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy](Paper80187.html) 222 - Versus for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial](Paper80462.html) - [Cooperating Effect of Rps14, Csnk1a1 and miRNA145/miRNA146a Haploinsufficiency in the Activation of the Innate Immune System in Del(5q) MDS](Paper85850.html) 386 - [The Extent of Labile Plasma Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial](Paper83197.html) 609 - [An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)](Paper85313.html) 912 - [Molecular Predictors MDS and after [Mutations cMYC Exon 2 Are a Rare but Recurrent Abnormality in Adult Patients with Acute Myeloid Leukemia (AML)](Paper87042.html) 1661 [Phase 3, and Acute Myeloid (AML): Assessment of Clinical Benefit, Safety, and Tolerability](Paper80199.html) - [Phase 2 Study of Monotherapy Galunisertib (LY2157299 Syndromes](Paper79075.html) 2099 - [Age and Gender-Related Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study](Paper78731.html) 2862 - [Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from PACE-MDS 2863 - [Romiplostim Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Leukemic Progression: Updated Results Patients Treated Hypomethylating Agents (HMA): A Report By the GFM](Paper81092.html) 2891 - [Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment](Paper82674.html) 3817 - [Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience](Paper79857.html) 4390 - [Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT](Paper84472.html) Plautz, W. Plekhanova, Plesa, T. 507 - 3029 - 3037 - [Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)](Paper79032.html) 3029 - [Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival](Paper85666.html) 3037 - [Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma](Paper79122.html) Pless, M. Plessa, - [Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data](Paper80563.html) 2554 - [Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score](Paper81926.html) 3742 - [Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Plomp, Ploski, R. Plotkin, L. I. Plougonven, E. Plouvier, E. 793 - 2492 - 3723 - 3734 - [t(12;21)/ETV6-RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and of EORTC Children 2492 [Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper85017.html) 3723 - [Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper81084.html) 3734 - [Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper84891.html) Plow, E. F. Plowden, T. C. Pluetschow, Pluijm, Acute Lymphoblastic Leukemia](Paper80031.html) 2495 - [A Double Blind Randomised Clinical Trial to Prevent Serious Side Effects of Dexamethasone during Pediatric Acute Lymphoblastic Leukemia Treatment](Paper78937.html) Plum, S. 3639 Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML](Paper81452.html) 3804 - of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia](Paper82946.html) Pluskota, E. Pluta, A. Martell, M. Poch Martell, M. 1921 - 1945 - 1948 - [Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion](Paper86621.html) 1945 - [Risk Factor Analysis for the Development of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation: Randomized Stratification and [Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen](Paper84608.html) Pocock, C. 347 - 812 - 1516 - 2689 - 4024 - [Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML](Paper84478.html) 812 - [A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: the and SAKK Lymphoma Groups (ISRCTN51837425)](Paper86301.html) 1516 - [Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs v 21 Trial](Paper81221.html) 4024 - [Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Leukaemia](Paper80118.html) J. Podack, Podaza, P. J. Podeltsev, N. A. A. N. 1138 - 3285 - 4100 - 4455 - [North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia](Paper79335.html) 3285 - [Comparative Effectiveness of Azacitidine Versus Inpatient Acute Leukemia: Results of a North American Web-Based Survey](Paper79184.html) Poe, J. C. Poeck, H. Poeck, - - [High Expression of the Hedgehog Transcription Factor GLI1 Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning](Paper85258.html) 2517 - [Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies](Paper84735.html) 2573 - [Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation](Paper80204.html) 3829 - [Prognostic Impact of Aberrant RUNX1 Expression in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation](Paper82564.html) 4398 - [Assessment of NPM1 Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation](Paper85361.html) Poetschger, U. Poetzsch, or Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide Bortezomib](Paper85083.html) 4258 - [High-Dose Carfilzomib G. Poh, W. Pohl, S. Pohlen, Pohlman, B. 1520 - 1920 - - 4167 - 4494 - Fludarabine and Busulfan Versus Fludarabine and 400 cGy Total Body Irradiation Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation for Busulfan Undergoing Autologous - [Standard Duration of Varicella Zoster Virus Prophylaxis May be Inadequate to Prevent Viral Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Front-Line Bendamustine Plus Rituximab](Paper81098.html) 4494 - [Association of Socioeconomic Status (SES) with Outcomes of Autologous Hematopoietic Cell Transplantation (ASCT) for 4364 - 4403 - [Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)](Paper82015.html) 3202 - [Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT](Paper82086.html) 4364 - [Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)](Paper81982.html) 4403 - [Allogeneic Hematopoietic Cell Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party and Pharmacodynamic of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper85017.html) 3734 - [Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)](Paper84891.html) Poirot, C. Pokiniewski, K. A. Pokrovskaya, O. S. Polak, A. 314 - 466 - 706 - 819 - 1436 - 1549 - 2455 - [FOXO1 Activation Is an of SYK and Inhibition in Tonic BCR Signal-Dependent Large B-Cell Lymphomas](Paper84390.html) 466 - [FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation and Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma](Paper84470.html) 1436 - [HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications](Paper84726.html) 1549 - [Activity of PIM Kinases Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving [MiR-155 Amplifies and NFkB Signaling Targeting Multiple Regulators of BCR Signal in DLBCL](Paper84740.html) Polak, R. Polan, Role of Impaired Erk1,2 Phosphorilation and Increased sIL2r Alpha Plasma Levels in the Reduced Frequency of Circulating T Regulatory Cells of Patients with Primary Myelofibrosis](Paper84579.html) 2809 - [Reduced Frequency of CD4+CD25++CD127low/-FOXP3+ Regulatory T Cells in Patients with Primary Myelofibrosis](Paper82488.html) 2833 - [V617FJAK2-Positive Endothelial Cells Are Present in Bone Marrow Neovessels of Patients with Myelofibrosis and Could Derive from the Transdifferentiation of Mutated Hematopoietic Cells](Paper82412.html) Polewski, P. Polfus, L. M. Polgarova, K. Polge, - 1858 - 1989 - 3226 - [Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT](Paper79685.html) 1858 - [Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Retrospective Single Center Experience](Paper85037.html) 1989 - [Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma (MM) Patients: A Prospective Multicenter Study](Paper82008.html) 3226 - [Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR](Paper83449.html) Polizzi, G. Polk, A. Pollak, K. I. Pollard, J. 799 - 800 - 1260 - [Treatment of 11q23/MLL+ AML with Gemtuzumab Ozogamicin: Results Oncology Group Trial AAML0531](Paper81618.html) 800 - [Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531](Paper83387.html) 1260 - [Genetic Variations in Calicheamicin Pathway Genes Are Predictors of - [Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients](Paper79073.html) 3862 - [Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients](Paper79057.html) Polliack, A. Pollock, D. M. Pollyea, D. 323 - 327 - 842 - 1443 - 2428 - 4104 - [Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial](Paper81999.html) 327 - [A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are to 65 Years and Not Eligible for Standard Induction Therapy](Paper84265.html) 842 - [Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function](Paper85940.html) 1443 - [IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience](Paper79849.html) 2428 - [Meningeoma-1 Cooperates and DOT1L Leukemia](Paper85157.html) 4104 [Characterization and of Syndrome Stem Pollyea, D. A. Poloni, A. Poloznikov, A. A. Polprasert, Polverelli, N. 1606 - 1614 - 4094 - [Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients](Paper84407.html) 1614 - [JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome](Paper84338.html) 4094 - [Crucial Factors of the Inflammatory Microenvironment (IL-1 Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in - 2896 - [Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy](Paper81414.html) 2896 - [A Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)](Paper83226.html) 2883 - [Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features](Paper78728.html) 2902 - [Validation of the Low Risk Prognostic Scoring System (LR-PSS) in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center](Paper85276.html) Pomerantz, R. Pomerantz, S. Pommerenke, C. Pompa, T. Ponce, D. M. 1911 - 2027 - 3231 - 4332 - [Impact of Busulphan Exposure on Transplant Outcomes for Patients with Advanced Myelodysplastic Syndromes Undergoing CD34 Selected Allogeneic Hematopoietic Cell Transplantation](Paper79776.html) 2027 - [Prospective Evaluation of Cord Blood (CB) & Haplo-Identical Donor Availability Reveals Compromised Donor Access for Both Graft Types in Minorities and High Rates of Failure to Clear Haplo Donors in Adult Patients](Paper83311.html) 3231 - [Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults Heparin (UFH) Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients](Paper86482.html) Poncz, M. 212 - [A Vascular Thrombocytopenia 2214 - [Engineered Donor Marrow Macrophages Phagocytose Cancer Cells and Aggressively Shrink Solid Tumor Xenografts Compared to Tumor Associated Macrophages](Paper83450.html) 2244 - [Membrane Remodeling Pathogenic Heparin-Induced Thrombocytopenia](Paper86018.html) 2266 - [Towards the Care of Hemophilia Induced Pluripotent Stem Cell (iPSC)-Derived Expressing FLI1 3454 - [A Microfluidic of Endothelial-Targeted Therapeutics](Paper86421.html) 3493 - [Thrombomodulin Fusion Proteins Coupled Anti-Thrombotic and Anti-Inflammatory Activity](Paper86861.html) - 4359 - [Exome Sequencing Informs Crenolanib](Paper83928.html) 3695 Relapsed/Refractory AML](Paper83493.html) 4359 of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant](Paper83994.html) Pondarre, C. 202 - 544 - [Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with Vector](Paper78442.html) [French National Drepagreffe Trial: Cognitive Performances and Neuroimaging at Enrollment and after 12 Months on Transfusion Program or Transplantation (AP-HP: NCT 01340404)](Paper78340.html) Pong, E. Pongtanakul, B. Poniewierska-Baran, A. Poniewierski, M. S. Ponisio, M. R. Ponka, P. 407 - 3352 - 3373 - [Interaction of Transferrin-Endosomes with Mitochondria: Treatment 1 Its Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations](Paper80448.html) 1547 - [Lenalidomide Maintenance Significantly Improves Progression-Free Survival with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial](Paper83168.html) Poola, H. Pooler, L. 61 - 397 - 2621 - [Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study)](Paper80661.html) 397 - [Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study)](Paper82231.html) 2621 - [Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT)](Paper80724.html) Poon, M. Y. C. Poon, M. 3191 - 4408 - [Multi-Center Study of Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Lymphoma, Nasal Type (ENKL)](Paper83818.html) 4408 - [Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL)](Paper86452.html) Poongkunran, C. Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial](Paper81038.html) 1850 - [Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens](Paper83180.html) Popat, U. R. 64 - 152 - 187 - 738 - 854 - 862 - 1190 - 1933 - 1980 - 1992 - 2003 - 2011 - 3128 - 3135 - 3136 - 3155 - 4408 - [A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome](Paper80186.html) 152 - [Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Unrelated Donors Hematopoietic Stem-Cell Transplantation](Paper82529.html) 187 - [Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Myeloma](Paper85061.html) 738 - [Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial](Paper83176.html) 854 - [A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids](Paper85377.html) 862 - [Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation with - [Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Transplantation Following Reduced Intensity Conditioning Regimens](Paper78284.html) 1933 - [Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?](Paper81945.html) 1980 - [Prospective Phase 2 Trial of Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM](Paper83730.html) 1992 - [Double Epigenetic Refractory or Poor-Risk Relapsed Lymphoma](Paper83892.html) 2003 - [Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Study](Paper78784.html) 2011 - [Bfr 3128 - [Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease](Paper82171.html) 3135 - 3136 - [Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit](Paper85991.html) 3155 - [Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma](Paper83552.html) 3186 - [Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients](Paper80956.html) By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials](Paper84093.html) 3194 - [Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant](Paper86152.html) 3225 - [Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience](Paper83731.html) 3324 - [Patient Choice and Lack of Medicare Coverage for HCT Are the Major Reasons Why Transplant Eligible Myelofibrosis Patients Do Not Undergo Transplant](Paper85900.html) 4321 - [Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation](Paper86323.html) 4342 - [Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype Are the Major Prognostic for Relapse after HCT](Paper78074.html) 4347 - [Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia](Paper78557.html) 4376 - [Clofarabine (Clo) Plus Busulfan (Bu) Is Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results](Paper80837.html) 4408 - [Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL)](Paper86452.html) Popescu, N. I. Pophali, P. A. Popov, A. Popov, S. Popova, M. O. Popovic, R. Popow-Kraupp, T. Popplewell, L. L. 519 - 522 - 578 - 1527 - 1961 - 2731 - 3179 - 3743 - 3931 - 3977 - [Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT](Paper79185.html) 522 - [Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation](Paper83188.html) 578 - [Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin in Patients with Relapsed/Refractory DLBCL](Paper78770.html) 1961 - [Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation](Paper78900.html) 2731 - [Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor BEAM Non-Hodgkin the Regimen Matter?](Paper83402.html) 3743 - [Combination of Dasatinib with Conventional Chemotherapy Is Associated with a High Response Rate in High Risk Acute Myeloid Leukemia (AML)](Paper86481.html) 3931 - [A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806](Paper82822.html) with - [Defining Patterns and Interactions Between Cells and Stromal Cells after in Utero Transplantation](Paper86524.html) 3097 - [A New Approach to Expand Cord Blood Derived Hematopoietic Stem Cells, Using Bioengineered Human Fetal Liver Tissue 3D-Constructs](Paper86885.html) Porcelijn, L. Porcher, J. C. Porco, Jr., J. A. Porcu, P. 589 - 3635 - 3983 - [Genome-Wide Mapping Reveals BRD4 T-Cell - Cutaneous T-Cell Lymphoma](Paper85011.html) 3983 - [Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma](Paper83974.html) Poret, E. Porkka, K. 343 - 477 - 479 - 867 - 1977 - 2462 - 3006 NK in Chronic Myeloid Leukemia Patients in Treatment Free Remission](Paper81002.html) 477 - [Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients](Paper78149.html) 479 - [Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase ENEST1st Stromal Cell-Induced Protection of AML](Paper84426.html) 1977 - [A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma](Paper81976.html) 2462 - [BCL2-Inhibitors Target a Major Group of Newly-Diagnosed Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo](Paper82622.html) 3006 - [Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease](Paper84640.html) 4022 - [Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients](Paper80957.html) 4033 - [Increased TACE Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)](Paper79530.html) Porosnicu Rodriguez, K. A. Porpaczy, E. A. Porras, J. Porrata, L. 1456 - 2683 - 3885 - [Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era](Paper83757.html) 2683 - [Treatment Patterns Failure of Front-Line Immunochemotherapy](Paper84189.html) 3885 - [Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma](Paper78441.html) Porrini, R. - 2821 - [Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?](Paper80717.html) 2815 - [The Platelet COUNT at Diagnosis Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis 1201 Patients](Paper83141.html) - [Application International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms](Paper85378.html) Porse, B. T. Portais, J. C. Portell, C. A. Porter, C. C. Porter, D. L. 183 - 681 - 683 - 719 - 852 - 920 - 1334 - 2523 - 2543 - - [Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas](Paper85949.html) 681 - [Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)](Paper85408.html) 683 - [Efficacy and Safety Humanized Chimeric Antigen Receptor (CAR)-Modified T Targeting Relapsed/ Refractory ALL](Paper79327.html) 719 - [Favorable in Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Multi-Center Study](Paper80707.html) 852 - [Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia](Paper83243.html) 920 - [Immunologic Effects of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis](Paper79423.html) 1334 - [Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)](Paper80826.html) 2523 - [Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies](Paper80623.html) 2543 - [Outcome of with Salvage High-Dose Cytarabine Monotherapy](Paper82642.html) 2929 - [Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia](Paper84967.html) 3154 - [Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report](Paper79609.html) 3183 - [Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma](Paper78082.html) 4380 - [Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation](Paper81953.html) Porter, J. B. 539 - 950 - 2156 - 3357 - 3366 - [Residual Erythropoiesis Protects Against Cardiac Iron Loading in Transfusion Dependent Thalassaemia (TDT) By Lowering Labile Plasma Iron (LPI) through 950 - Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in -Thalassemia](Paper86877.html) 2153 - [Optimizing Iron Chelation Therapy with Deferasirox for Open-Label Thetis Study](Paper79080.html) 2155 - [Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with and Deferoxamine- Extension of Cordelia Study](Paper80463.html) 2156 - [Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years](Paper80641.html) 3357 - [A Potential Novel Application of Eltrombopag: A Agent to Enhance Iron Chelation Therapy](Paper79350.html) 3366 - [Efficacy of Deferasirox Thalassemia Syndromes: 1-Year Results from the Thetis Study](Paper79097.html) Porter, Porteus, H. Portlock, C. S. 2668 - 2691 - 4383 - [Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive [Veliparib (ABT-888), Bendamustine, and Rituximab Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma](Paper84188.html) 4383 - [A Prospective of in Refractory Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant Thrombosis Study (LATS)](Paper85460.html) 653 - [Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study](Paper85615.html) 3555 - [Annexin A5 Resistance Is Associated with Thrombotic Risk in Patients with the Lupus Anticoagulant: The Anticoagulant and 3367 - [Association Between Serum Ferritin and Liver Iron Concentration with Cardiac Iron in Pediatric Thalassemia Major Patients](Paper78122.html) 2154 Patients: A Retrospective from the Myocardial Iron in Thalassemia (MIOT) Network](Paper78135.html) 2159 - [Deferiprone Has Dose-Dependent Effect on Liver Iron Concentration](Paper81168.html) 3367 - [Changes of Cardiac Iron and Function during Pregnancy in Trasfusion-Dependent Thalassemia Patients](Paper79552.html) Pospisilova, S. Pospisilova, Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations](Paper80448.html) 2921 - [Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?](Paper80972.html) 4142 - [Tp63 Contributes to the Apoptosis [Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Negative By Whole Exome Sequencing (WES) Analysis](Paper85431.html) 2913 - [Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia](Paper85266.html) 4139 - [Single Cell Analysis of IG Genes in CLL: Cases with Multiple IGH Rearrangements Are Constituted of Several Independent Clones Even When Indistinguishable By Flow Cytometry](Paper81046.html) Possemato, A. Post, S. M. 439 - 468 - 2476 - [hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of of hnRNP K Drives c-Myc-Dependent Malignancies Represent a Novel Therapeutic Opportunity for Hematologic Malignancies](Paper81377.html) 2476 - [Developing Therapeutic Strategies Postel-Vinay, S. Postelnek, J. A. 27 - 3034 - [Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial](Paper79113.html) 3034 - [Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice](Paper79826.html) Potchanant, E. S. Potluri, J. 327 - [A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are to 65 Years and Not Eligible for Standard Induction Therapy](Paper84265.html) 715 - [Preliminary Results of a Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Chronic Lymphocytic after Refractory to Ibrutinib - 3978 - [Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms](Paper82461.html) 2685 - [LRPAP1 Is a in Mantle Cell Lymphoma (MCL)](Paper80853.html) 3978 - [Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Plus Bendamustine Versus Bendamustine in Relapsed/Refractory M. 876 - 4478 - [Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors](Paper81284.html) 4478 - [Evaluation of Cardiovascular Disease Risk in Chronic Myelogenous Leukemia Patients Using Electronic Medical Records from Community-Based Oncology Practices in the United States](Paper81427.html) Potter, M. 1499 4399 - [Improved Survival in T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012](Paper81703.html) 4399 - [Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)](Paper85432.html) Potter, M. Potter, N. Potter, V. T. 3129 - [Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease](Paper82890.html) Pouaty, C. Poulain, S. Poulart, V. Pouliot, G. Poulos, M. G. Poultsides, G. Pounds, S. Pouquet, M. Pour, L. Pour, L. 30 - 392 - 727 - 729 - 927 - 1844 - 4250 - [Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)](Paper82083.html) 392 - [Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial](Paper78741.html) 727 - [Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)](Paper79829.html) 729 - [Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)](Paper81814.html) 927 - [Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients](Paper79550.html) 1844 - [Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup](Paper82133.html) 4250 - [Serial Echocardiographic Assessment of Patients (Pts) Myeloma Carfilzomib 3 Pourdehnad, M. 1494 - 4007 - [CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma](Paper84929.html) 4007 - [CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity](Paper85880.html) Pourdehnad, M. 1738 - 2704 - [CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse](Paper83578.html) 2704 - [CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma](Paper85948.html) Pouthier, F. Powell, B. L. 217 - 319 - 342 - 2102 - 2556 - [North American Leukemia Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age 60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)](Paper80738.html) 319 - [Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)](Paper77589.html) 342 - [Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R](Paper85773.html) 2102 - [Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)](Paper81466.html) 2556 - [The Mitochondrial High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)](Paper79012.html) Powell, B. Powell, C. Powell, H. Powell, J. S. 1082 - 2292 - 3508 - [Human Chorionic Villus Stem during Gestation](Paper87066.html) and Unbound Components Influence Intrauterine Chorionic Villus Stem Cell Transplantation](Paper86826.html) Powell, J. D. Powell, M. A. Power, M. M. Powers, J. M. Powers, J. Powner, D. J. Poynter, J. N. Pozdnyakova, O. Poziopoulos, G. 1706 - 1720 - 2925 - [CD49d Prevails over the Novel Recurrent Mutations As Independent Prognosticator of Overall Survival in Chronic Lymphocytic Leukemia](Paper78412.html) 1720 - [The Concomitant High Expression of Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Low-Risk 1465 - 3862 - [Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients](Paper79073.html) 3862 - [Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients](Paper79057.html) Pozzi, S. Pozzo, F. Prabahran, A. A. Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)](Paper79530.html) Prstekjr Cramer, E. Prahl, M. 1306 - 1310 - [Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study](Paper82957.html) 1310 - [Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies](Paper82908.html) Prakash, G. Stromal Genes By Whole Exome and Interaction Large B-Cell Lymphoma](Paper84679.html) 3322 - [High Risk Apml Treated Successfully with Four Cycles of ATO and ATRA Combination in Resource Constrained Settings](Paper84191.html) 4386 - [Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Transplant Registry (ISCTR) [Marqibo\u00ae, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population](Paper87149.html) 2491 - [Plasma Vincristine Levels Are 100-Fold Higher with Marqibo\u00ae(Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)](Paper87103.html) Prasad, M. Prasad, - 2514 - 4395 - [Exploring the Expression Profile of Long Non-Coding RNA in Different Acute Myeloid [Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012](Paper84413.html) 2514 - [Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 4395 - [Feasibility and Allogeneic Hematopoietic Stem-Cell High-Risk AML: Real-Life Perspective from a Single Institution](Paper84488.html) Prathibha, R. Pratt, G. 167 - 394 - 1746 - 1981 - 3258 - [Kinetics of CLL Subclonal Spontaneous Treatment-Induced 394 - [A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial](Paper81198.html) 1746 - [UCHL1 Is a New Therapeutic Target in Lymphoid Malignancies, Independent of ATM and TP53 status](Paper84411.html) 1981 - [Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial](Paper84484.html) 3258 - [Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation](Paper80455.html) Pratt, K. P. Pratz, K. 217 - 327 - 771 - 1361 - 3164 - [North American Leukemia Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age 60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)](Paper80738.html) 327 - [A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are to 65 Years and Not Eligible for Standard Induction Therapy](Paper84265.html) 771 - [Liberal Vs. Restrictive Transfusion Thresholds Patients: A Feasibility Pilot Study](Paper81746.html) 1361 - [A Phase 1 Study of the PARP Veliparib in Combination with Temozolomide in Acute - [Prospective Study of Peri-Transplant Use of Sorafenib Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation](Paper86212.html) M. Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)](Paper79530.html) 2712 - [Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry - Lymphoma, of Lymphoma Registry in Thailand](Paper82734.html) Prchal, J. T. 936 - 2832 2835 3335 - 3348 - - 4086 - [Thrombotic Complications Are Associated with Phlebotomy Therapy in Patients with Chuvash Polycythemia](Paper85217.html) 2832 - [Digital Immune Expression Profiling Coupled with Immunohistochemistry for Interrogation of Microenvironment in Formalin Fixed Paraffin Embedded Specimens of Marrow and Spleen from PMF Patients](Paper86358.html) 2835 - [A Novel Erythroid Regulator MLF1IP Promotes Mice By Regulating Cell Cycle](Paper79757.html) 3332 - [Tibetan Gain-of-Function Variant Selected SNPs of HIF-2-Alpha (EPAS1) Are Associated with Lower Hemoglobin Values in Tibetans](Paper82172.html) 3335 - [Polycythemia of Mice with Human Gain-of-Function EPOR (mtHEPOR) Is Transiently Corrected in Perinatal Life in with Low Epo and Increased Erythrocyte Phosphatidylserine Exposure](Paper86517.html) 3348 - [Absence of Polycythemia (OSA) Is Caused By Neocytolysis](Paper86357.html) 3371 - [Sickle Cell Anemia in a Child with Three -Globin Clusters (-S/-S, -A): Loss of LCR and 3' HS1 the -Globin Not Abrogate Its Transcript](Paper78870.html) of the X-Chromosome Genes PV Prebet, T. 95 - 960 1138 - 2900 - 3285 - 4455 - [Outcome of Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy](Paper80187.html) 960 - [Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies](Paper82862.html) 1138 - [North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia](Paper79335.html) 2900 - [A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Study](Paper80176.html) 3285 - [Comparative Effectiveness of North American Web-Based Survey](Paper79184.html) Preblick, - - Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response](Paper84752.html) 1598 - [Long-Term Follow-up in Very Elderly Myeloid Leukemia Treated with Imatinib Frontline](Paper83806.html) 2735 - [The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)](Paper83041.html) 2792 - Outcome CML WP Analysis](Paper82401.html) 4040 - [Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase](Paper82326.html) Preijers, F. Preis, A. Presch, I. Prescott, J. Presgrave, P. Press, A. Press, K. R. Press, O. W. 118 - 1498 - 1518 - 1972 - 2678 - Novel Bispecific CD38 Yttrium-90-DOTA Capture](Paper80940.html) 1498 - [Feasibility of Interim PET-Adapted Advanced Phase Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study](Paper83332.html) 1972 - [Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma](Paper78986.html) 2678 - [Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016](Paper83927.html) 2728 - a Phase I-II Rituximab 4428 - [Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab](Paper85708.html) Press, R. D. Pressel, S. L. Pressler, J. 2859 - 2891 - [Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)](Paper84614.html) 2891 - [Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment](Paper82674.html) Pressnail, B. Prete, A. Preudhomme, 1307 - 2568 - 2581 - 3833 - [Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)](Paper81031.html) 302 - [ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis](Paper85816.html) 1307 - [HFE Gene Mutation Status Response to Gemtuzumab Ozogamicin in AML](Paper85777.html) 2568 - [Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group](Paper78868.html) 2581 - [NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group](Paper81774.html) 3833 - [Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation](Paper82607.html) Preudhomme, C. Preus, L. 61 - 397 - 2621 - [Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study)](Paper80661.html) 397 - [Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study)](Paper82231.html) 2621 - [Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT)](Paper80724.html) Preuss, K. D. 1817 - 2685 - 3995 - [Peripheral B Cells from Patients with MGUS and Multiple Myeloma (MM) Can Be Stimulated by Paraprotein-Target Specific T-Helper Cells to Produce Paraprotein-Identical Monoclonal Antibodies: Rationale for PARs, a Novel Therapeutic Approach with Ultimate Specificity in MGUS/MM](Paper84832.html) 2685 - [LRPAP1 Is a Frequent B-Cell Receptor Cell Lymphoma (MCL)](Paper80853.html) 3995 - [BARs (B-cell receptor antigens for reverse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms](Paper82531.html) Prevalsek, D. Prezioso, I. Prezotti, A. N. 3530 - [Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience](Paper84218.html) 3863 - [Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre](Paper82347.html) Prica, A. Price, A. E. Price, D. J. Price, Jr., F. W. Price, J. Price, K. Price, V. E. 1117 - 2074 - [Assessing Incidence of and Risk Predictors Ascertained at Diagnosis for Symptomatic Venous Thrombotic Events in Pediatric Cancer Patients: A 20-Year Population Based Study from the Maritimes, Canada](Paper84835.html) 2074 - [Management Experience of Peripherally Inserted Central Catheters in Pediatric Oncology Patients: A 15 Year Population-Based Study P. Primo, D. Prina-Mello, A. Prince, G. T. 771 - 1351 - 3427 - [Liberal Vs. Restrictive Transfusion Thresholds in Patients: Feasibility Study](Paper81746.html) 1351 - [Immune Modulation with Pomalidomide after Diagnosed Acute Myeloid Leukemia (AML)](Paper86200.html) 3427 - [Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile](Paper80164.html) Prince, H. M. Prince, H. M. Prince, R. Princic, N. Prine, B. Prior, S. M. Pristupa, A. 1732 - 2936 - [Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic 2936 - [Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 of Ibrutinib Combined with Bendamustine/Rituximab](Paper79007.html) Pristupa, A. Pritchard, R. R. Priyanka, P. 1392 - 1703 - [Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups](Paper84207.html) 1703 - [Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R](Paper85687.html) Pro, B. 1537 - 2694 2694 - [Brentuximab Vedotin in Combination with Multi-Agent Chemotherapy Is Well Tolerated and Shows Promising Activity As Frontline Treatment for Primary Mediastinal B-Cell Lymphoma](Paper85376.html) 3892 - [Metabolic Patterns in Cancer Diffuse Large B-Cell Lymphoma: Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival](Paper79819.html) 2961 [The Alternate Activation of Hedgehog Pathway, Either in CD138+ or in CD138-CD19+ Multiple Myeloma Primary Cells, Impacts on Disease Outcome](Paper80482.html) Prochazkova, J. Prochorec-Sobieszek, M. 314 - 466 - 819 - [FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Large B-Cell Lymphomas](Paper84390.html) 466 - [FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized By Enhanced Oxidative Phosphorylation](Paper84507.html) PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma](Paper84470.html) Prochorec-Sobieszek, M. Prockop, S. Prockop, S. Proetel, U. Prokaeva, T. Promny, I. Pronschinske, K. B. Prosper, F. 23 - 117 - 2955 - 4180 - [Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma](Paper83631.html) 117 - [Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody - [Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients](Paper81697.html) 4180 - [Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)](Paper80476.html) Prosper, O. Proszek, P. 371 Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing](Paper81201.html) 2981 - [Specific Identification of High Risk Disease Molecular Profiling By (Myeloma of Their - an Analysis of 1,036 Trial M. Prouet, Provost, S. 4106 - 4113 - [Age-Associated Acquired Mutations in Hematopoietic Cells Predominantly Affect Epigenetic Regulators TET2 and DNMT3A and Are Associated with Distinct Biological and Hematological Profiles](Paper84993.html) 4113 - [Human Blood Cell Level of 5-Hydroxymethylcytosine (5hmC) Declines Steadily during Aging and Is Multifactorial](Paper85143.html) Prov\u00f4t, F. Prudent, R. Prudente, Z. Prudhomme, L. S. Testing Diagnosis of Platelet Disorders: A Single Center Experience](Paper79323.html) 3476 - [Platelet Transmission Electron Microscopy and Flow Cytometry in the Diagnosis of Congenital/Hereditary Qualitative or Quantitative Platelet Pruthy, M. Przekopowitz, Przychodzen, B. 86 - 300 - 607 - 611 - 709 - 740 - 1259 - 1319 - 1350 - 1405 - 1645 - 3897 - [The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML)](Paper83477.html) 300 - [Impact of Eltrombopag on Expansion Clones Somatic Mutations Refractory Aplastic Anemia](Paper86231.html) Prognostic Scoring System \"Molecular\" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS)](Paper83638.html) 611 - [Network-Based Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing](Paper83074.html) 740 - [Prognostic Impact of Molecular Mutations in Acute Leukemia (AML) 1259 - [PHF6 Somatic Mutations Pathophysiology of MDS and AML](Paper86821.html) 1319 - [Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy](Paper84264.html) 1350 - [Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression 1405 - [Whole-Exome Sequencing - [TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition](Paper83115.html) - [Downregulation of BAP1 in with a Post-Translational Reduction of BRCA1 Levels of Promoter Methylation](Paper83716.html) 1652 - [Myelodysplastic Syndrome (MDS)-Determining Clonal - [Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia](Paper85057.html) 2848 - [Determinants of Phenotypic Commitment and Clonal from the of Clonal Architecture in CMML](Paper86610.html) 2853 - [Molecular Predictors of Treated Lenalidomide](Paper86719.html) 3788 - [Ex Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used As Adjuvants to Regular Chemotherapy in IDH1/2-Mutated Acute Myeloid Leukemia](Paper86972.html) 3825 - [Prognostic Impact of in AML at First Relapse](Paper81706.html) 3897 - [Novel Findings for the Role of Microenvironment and Heat Shock Proteins (HSP) in B -Cell Recptor (BCR) Activation, Disease Progression and of (FL): Gene Expression Profiling (GEP) and New Pathways for Psaltopoulou, T. Psarra, K. Psatha, N. Psimenou, E. Ptaszynski, M. Pu, J. J. Puccini, B. 2483 - 3985 - [Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim a Multicenter 3985 - [LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Lymphoma [Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Inhibitors Population Analysis](Paper79034.html) 4254 - [Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective](Paper79092.html) Puente, X. S. Puerta, J. M. 2776 - 2786 - [Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method](Paper80215.html) 2786 - [Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients](Paper84694.html) Puerta, P. Puerta Puerta, J. M. Pugh, K. 331 - 812 - 2669 - [Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)](Paper86038.html) 812 - [A Prospective Randomised of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: the Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial](Paper86276.html) Pugh, T. J. Pugin, A. G. 1985 - [Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity](Paper79536.html) Pui, C. H. 692 - 693 - 695 877 - 1299 - 1421 - 3255 - - 693 - [Expression of an Oncogenic B-Progenitor - [Germline to Childhood Acute Lymphoblastic Leukemia](Paper83830.html) 877 - [Cognitive, Behavior and Academic Problems in Adolescent Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study](Paper79434.html) 1299 - [Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia](Paper81709.html) 1421 - [High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia](Paper86918.html) 3255 - [Association Between Acute Leukoencephalopathy and Long-Term Neurobehavioral and Brain Imaging Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only](Paper79163.html) 3714 - [Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients](Paper82578.html) Puig, N. 19 - 367 - 721 - 725 - 1694 - 1848 - 2963 - 2971 - 4180 - 4243 - 4356 - SCI-52 - [Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials](Paper81690.html) 367 - [Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)](Paper80461.html) 721 - [Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study](Paper81654.html) 725 - [What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity](Paper81675.html) 1694 - [PD-1 but Not in the \"Classical CD14+CD16-\" Monocytes in the Peripheral Blood [Bortezomib, Melphalan, Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years](Paper83068.html) (MM)](Paper81605.html) 2971 - [Genetic Characterization of Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients](Paper83061.html) 4180 - [Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)](Paper80476.html) 4181 - [The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients](Paper81680.html) 4243 Followed Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)](Paper81735.html) 4356 - [Immunoparesis Recovery As Predictor Marker of Progression after Autologous Stem Cell Transplantation in Multiple Myeloma](Paper80760.html) SCI-52 - [Characterization of Minimal Residual Disease](Paper77256.html) Puissant, 2472 - Activation PI3K/mTOR Resistance to Sorafenib in AML](Paper79052.html) 2958 - of the Multiple Myeloma](Paper78312.html) 3674 - CKMT1B AML](Paper86645.html) Pujade-Lauraine, E. Pujals, A. Pula, B. Pule, Puliyel, M. Pullarkat, V. 792 - 3857 - [8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML](Paper86583.html) 3857 - [Proteomics Profiling of Leukemia Derived Exosomes: A Potential Role in Leukemic Transformation](Paper86431.html) Pulsipher, M. A. 1949 - SCI-34 - [A Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for of Therapy Lymphocytic Leukemia: Pivotal Role of Minimal Residual Disease](Paper77209.html) Pulsoni, Pundhir, - 4040 - [REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data](Paper83161.html) 2775 - [Imatinib Suspension and Open-Label, Dose-Finding Study Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts \u00d7 \u00d7 109/L) 3645 - [GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment](Paper78730.html) 4040 - [Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase](Paper82326.html) J. CLL Clinical Trials](Paper82726.html) 3971 - [Prevalence and Prognostic Value of and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study](Paper78694.html) Punwani, Punzalan, R. Punzel, I. Pusciznova, P. Pusic, I. 689 - 1935 - 1950 - 3144 - [Dynamic Changes in Clonal Clearance with Decitabine Therapy AML and MDS - Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results](Paper82290.html) 1950 - HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes](Paper84194.html) 3144 - [Addition of Mycophenolate Mofetil to Methotrexate and Not Reduced Allogeneic Hematopoietic Cell Transplantation](Paper80769.html) of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients](Paper81179.html) 2146 - [Different Thresholds of Serum Ferritin Levels for of Liver Iron Concentration in Hemoglobinopathies](Paper81019.html) 2158 - [Three Dimensional Speckle Tracking Echocardiography (3D-STE) for Early Detection of Subtle Myocardial Deformation Thalassemic Patients](Paper84213.html) 2305 - [Could Hemorrhagic Thrombotic Risk Identified By Coagulative Tests Using Fibtem and Antithrombin Levels? A Single Centre Study](Paper85972.html) 2788 - [Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience](Paper84813.html) Putz, M. Putzulu, R. Puvvada, S. Puy, H. Puyade, 393 - 456 - Thalidomide Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM Neoplasm (BPDCN) Patients : Results on Patients of the French BPDCN Network](Paper81980.html) Puzanov, I. Pwu, R. F. Pylypenko, H. 2936 - 2938 - [Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 of Ibrutinib Combined with Bendamustine/Rituximab](Paper79007.html) 2938 - [Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)](Paper80701.html) Pyzer, A. R. "}